{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:30Z","timestamp":1793647290215,"version":"4.5.1"},"reference-count":559,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00957-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:55:10Z","timestamp":1783086910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence"],"prefix":"10.1186","volume":"14","author":[{"given":"Farshad","family":"Heydari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Zendehdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa Manafi","family":"Varkiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Derakhshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Anvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Farhid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Naghinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"1","key":"957_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","volume":"10","author":"J Nors","year":"2024","unstructured":"Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. JAMA Oncol. 2024;10(1):54\u201362. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5098.","journal-title":"JAMA Oncol"},{"issue":"1","key":"957_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/crst.crst_209_23","volume":"7","author":"P Poolakkil","year":"2024","unstructured":"Poolakkil P, Pareekutty NM, Balasubramanian S, Nethrakare A, Anilkumar B. Real-world data on the pattern of recurrence of colorectal cancer at a tertiary cancer center in South India: a retrospective observational study. Cancer Res Stat Treat. 2024;7(1):36\u201344. https:\/\/doi.org\/10.4103\/crst.crst_209_23.","journal-title":"Cancer Res, Stat, Treat"},{"issue":"5","key":"957_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","volume":"165","author":"R Rajaram","year":"2024","unstructured":"Rajaram R, Huang Q, Li RZ, Chandran U, Zhang Y, Amos TB, et al. Recurrence-free survival in patients with surgically resected non-small cell lung cancer: a systematic literature review and meta-analysis. Chest. 2024;165(5):1260\u201370. https:\/\/doi.org\/10.1016\/j.chest.2023.11.042.","journal-title":"Chest"},{"issue":"3","key":"957_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1245\/s10434-010-1442-0","volume":"18","author":"LA Aliperti","year":"2011","unstructured":"Aliperti LA, Predina JD, Vachani A, Singhal S. Local and systemic recurrence is the achilles heel of cancer surgery. Ann Surg Oncol. 2011;18(3):603\u201307. https:\/\/doi.org\/10.1245\/s10434-010-1442-0.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"957_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.dld.2023.11.041","volume":"56","author":"V Balboa-Barreiro","year":"2024","unstructured":"Balboa-Barreiro V, P\u00e9rtega-D\u00edaz S, Garc\u00eda-Rodr\u00edguez T, Gonz\u00e1lez-Mart\u00edn C, Pardeiro-P\u00e9rtega R, Y\u00e1\u00f1ez-Gonz\u00e1lez-Dopeso L, et al. Colorectal cancer recurrence and its impact on survival after curative surgery: an analysis based on multistate models. Digestive Liver Disease. 2024;56(7):1229\u201336. https:\/\/doi.org\/10.1016\/j.dld.2023.11.041.","journal-title":"Digestive Liver Disease"},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"1575813","DOI":"10.3389\/fonc.2025.1575813","volume":"15","author":"R Aguiar-Ib\u00e1\u00f1ez","year":"2025","unstructured":"Aguiar-Ib\u00e1\u00f1ez R, Mbous YPV, Sharma S, Chawla E, Pawar D. Clinical, humanistic and economic burden associated with recurrence among patients with early-stage cancers: a systematic literature review. Front Oncol. 2025;15:1575813. https:\/\/doi.org\/10.3389\/fonc.2025.1575813.","journal-title":"Front Oncol"},{"issue":"4","key":"957_CR7","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/curroncol29040223","volume":"29","author":"R Garaszczuk","year":"2022","unstructured":"Garaszczuk R, Yong JHE, Sun Z, de Oliveira C. The economic burden of cancer in Canada from a societal perspective. Curr Oncol. 2022;29(4):2735\u201348. https:\/\/doi.org\/10.3390\/curroncol29040223.","journal-title":"Curr Oncol"},{"issue":"4","key":"957_CR8","doi-asserted-by":"publisher","first-page":"100487","DOI":"10.1016\/j.jtocrr.2023.100487","volume":"4","author":"JM Lee","year":"2023","unstructured":"Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS. Economic burden of recurrence among resected medicare patients with early stage NSCLC. JTO Clin Res Rep. 2023;4(4):100487. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100487.","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"957_CR9","doi-asserted-by":"publisher","first-page":"110425","DOI":"10.1016\/j.ejso.2025.110425","volume":"51","author":"A Bonis","year":"2025","unstructured":"Bonis A, Detterbeck F, Figueroa PU, Chen H, Osarogiagbon R, Dell\u2019amore A, et al. Classification of recurrence patterns in surgically treated non-small cell lung cancer \u2013 a systematic review and a call for standardization. Eur J Surg Oncol. 2025;51(11):110425. https:\/\/doi.org\/10.1016\/j.ejso.2025.110425.","journal-title":"Eur J Surg Oncol"},{"issue":"7341","key":"957_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bmj.324.7341.813","volume":"324","author":"AG Renehan","year":"2002","unstructured":"Renehan AG, Egger M, Saunders MP, O\u2019Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813. https:\/\/doi.org\/10.1136\/bmj.324.7341.813.","journal-title":"BMJ"},{"issue":"11","key":"957_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s10350-007-9030-5","volume":"50","author":"JJ Tjandra","year":"2007","unstructured":"Tjandra JJ, Chan MKY. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50(11):1783\u201399. https:\/\/doi.org\/10.1007\/s10350-007-9030-5.","journal-title":"Dis Colon Rectum"},{"issue":"22","key":"957_CR12","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","volume":"11","author":"A Johnson","year":"2022","unstructured":"Johnson A, Townsend M, O\u2019Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-Cell advancement in solid tumors. Cells. 2022;11(22):3626. https:\/\/doi.org\/10.3390\/cells11223626.","journal-title":"Cells"},{"key":"957_CR13","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2024;15:1519671. https:\/\/doi.org\/10.3389\/fimmu.2024.1519671.","journal-title":"Front Immunol"},{"issue":"11","key":"957_CR14","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med. 2025;6(11):102353. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","journal-title":"Cell Rep. Med"},{"key":"957_CR15","doi-asserted-by":"publisher","first-page":"1638186","DOI":"10.3389\/fimmu.2025.1638186","volume":"16","author":"T Andreou","year":"2025","unstructured":"Andreou T, Neophytou C, Kalli M, Mpekris F, Stylianopoulos T. Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Front Immunol. 2025;16:1638186. https:\/\/doi.org\/10.3389\/fimmu.2025.1638186.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"MC Vo","year":"2025","unstructured":"Vo MC, Tran VDH, Nguyen VT, Ruzimurodov N, Trung DT, Kim SK, et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: Why are approvals restricted to hematologic malignancies? J Hematol Oncol. 2025;18(1):91. https:\/\/doi.org\/10.1186\/s13045-025-01744-9.","journal-title":"J Hematol Oncol"},{"key":"957_CR17","doi-asserted-by":"publisher","first-page":"1063454","DOI":"10.3389\/fimmu.2023.1063454","volume":"14","author":"Y Kong","year":"2023","unstructured":"Kong Y, Tang L, You Y, Li Q, Zhu X. Analysis of causes for poor persistence of CAR-T cell therapy in vivo. Front Immunol. 2023;14:1063454. https:\/\/doi.org\/10.3389\/fimmu.2023.1063454.","journal-title":"Front Immunol"},{"issue":"10","key":"957_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biom15101407","volume":"15","author":"S Smirnov","year":"2025","unstructured":"Smirnov S, Zaritsky Y, Silonov S, Gavrilova A, Fonin A. Advancing CAR-T therapy for solid tumors: from barriers to clinical progress. Biomolecules. 2025;15(10):1407. https:\/\/doi.org\/10.3390\/biom15101407.","journal-title":"Biomolecules"},{"key":"957_CR19","doi-asserted-by":"publisher","unstructured":"Liang X. CAR T-cell therapy failure in solid tumors as a problem of temporal signal integration. J Educ Chang High Sch Sci. 2026;10(1). https:\/\/doi.org\/10.64336\/001c.155592.","DOI":"10.64336\/001c.155592"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"114583","DOI":"10.1016\/j.jconrel.2025.114583","volume":"391","author":"P Rehorst","year":"2025","unstructured":"Rehorst P, Kros A. A general logic-gating framework for CAR-T and nanocarrier cancer therapies: a cross-platform comparative analysis of logic architectures and their molecular implementation strategies. J Control Release. 2025;391:114583. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114583.","journal-title":"J Control Release"},{"issue":"3","key":"957_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"957_CR22","doi-asserted-by":"publisher","first-page":"1520488","DOI":"10.3389\/fphar.2024.1520488","volume":"15","author":"A Contursi","year":"2024","unstructured":"Contursi A, Tacconelli S, Di Berardino S, De Michele A, Patrignani P. Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention. Front Pharmacol. 2024;15:1520488. https:\/\/doi.org\/10.3389\/fphar.2024.1520488.","journal-title":"Front Pharmacol"},{"key":"957_CR23","doi-asserted-by":"publisher","unstructured":"Raskov H, Orhan A, Agerb\u00e6k M, G\u00f6genur I. The impact of platelets on the metastatic potential of tumour cells. Heliyon. 2024;10(14):e34361. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34361.","DOI":"10.1016\/j.heliyon.2024.e34361"},{"issue":"2","key":"957_CR24","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.ajps.2024.100907","volume":"19","author":"J Guo","year":"2024","unstructured":"Guo J, Cui B, Zheng J, Yu C, Zheng X, Yi L, et al. Platelet-derived microparticles and their cargos: the past, present and future. Asian J Pharm Sci. 2024;19(2):100907. https:\/\/doi.org\/10.1016\/j.ajps.2024.100907.","journal-title":"Asian J Pharm Sci"},{"issue":"5","key":"957_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17425247.2023.2217378","volume":"20","author":"D Cacic","year":"2023","unstructured":"Cacic D, Hervig T, Reikvam H. Platelets for advanced drug delivery in cancer. Expert Opin Drug Delivery. 2023;20(5):673\u201388. https:\/\/doi.org\/10.1080\/17425247.2023.2217378.","journal-title":"Expert Opin Drug Delivery"},{"key":"957_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2024.07.013","volume":"373","author":"A Safdar","year":"2024","unstructured":"Safdar A, Wang P, Muhaymin A, Nie G, Li S. From bench to bedside: platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery. J Control Release. 2024;373:128\u201344. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.013.","journal-title":"J Control Release"},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"1026386","DOI":"10.3389\/fphar.2022.1026386","volume":"13","author":"Z Dai","year":"2022","unstructured":"Dai Z, Zhao T, Song N, Pan K, Yang Y, Zhu X, et al. Platelets and platelet extracellular vesicles in drug delivery therapy: a review of the current status and future prospects. Front Pharmacol. 2022;13:1026386. https:\/\/doi.org\/10.3389\/fphar.2022.1026386.","journal-title":"Front Pharmacol"},{"key":"957_CR28","doi-asserted-by":"publisher","unstructured":"Fatima S. Tumor microenvironment: a complex landscape of cancer development and drug resistance. Cureus. 2025;17(4):e82090. https:\/\/doi.org\/10.7759\/cureus.82090.","DOI":"10.7759\/cureus.82090"},{"issue":"10","key":"957_CR29","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/cancers15102750","volume":"15","author":"M Nikfar","year":"2023","unstructured":"Nikfar M, Mi H, Gong C, Kimko H, Popel AS. Quantifying intratumoral heterogeneity and immunoarchitecture generated in-silico by a spatial quantitative systems pharmacology model. Cancers (Basel). 2023;15(10):2750. https:\/\/doi.org\/10.3390\/cancers15102750.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"957_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu YC, Liang SB, Luo M, Wang XP. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 2025;25(1):103. https:\/\/doi.org\/10.1186\/s12935-025-03734-w.","journal-title":"Cancer Cell Int"},{"key":"957_CR31","doi-asserted-by":"publisher","first-page":"217385","DOI":"10.1016\/j.canlet.2024.217385","volume":"611","author":"H Yu","year":"2025","unstructured":"Yu H, Li J, Peng S, Liu Q, Chen D, He Z, et al. Tumor microenvironment: nurturing cancer cells for immunoevasion and druggable vulnerabilities for cancer immunotherapy. Cancer Lett. 2025;611:217385. https:\/\/doi.org\/10.1016\/j.canlet.2024.217385.","journal-title":"Cancer Lett"},{"issue":"6","key":"957_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ijc.2910370614","volume":"37","author":"CK Luk","year":"1986","unstructured":"Luk CK, Sutherland RM. Influence of growth phase, nutrition and hypoxia on heterogeneity of cellular buoyant densities in in vitro tumor model systems. Intl J Cancer. 1986;37(6):883\u201390. https:\/\/doi.org\/10.1002\/ijc.2910370614.","journal-title":"Intl J Cancer"},{"issue":"1","key":"957_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Sig Transduct Target Ther. 2021;6(1):153. https:\/\/doi.org\/10.1038\/s41392-021-00544-0.","journal-title":"Sig Transduct Target Ther"},{"key":"957_CR34","doi-asserted-by":"publisher","first-page":"1367875","DOI":"10.3389\/fimmu.2024.1367875","volume":"15","author":"P Leone","year":"2024","unstructured":"Leone P, Malerba E, Susca N, Favoino E, Perosa F, Brunori G, et al. Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol. 2024;15:1367875. https:\/\/doi.org\/10.3389\/fimmu.2024.1367875.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","volume":"14","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhang B. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer. Exp Hematol Oncol. 2025;14(1):54. https:\/\/doi.org\/10.1186\/s40164-025-00647-2.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"957_CR36","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.trecan.2025.04.004","volume":"11","author":"AM Finger","year":"2025","unstructured":"Finger AM, Hendley AM, Figueroa D, Gonzalez H, Weaver VM. Tissue mechanics in tumor heterogeneity and aggression. Trends Cancer. 2025;11(8):806\u201324. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.004.","journal-title":"Trends Cancer"},{"key":"957_CR37","doi-asserted-by":"publisher","unstructured":"Enjalbert R, K\u00f6ry J, Kr\u00fcger T, Bernabeu MO. Abnormal vasculature reduces overlap between drugs and oxygen in a tumour computational model: implications for therapeutic efficacy. PLoS Comput Biol. 2025;21(12):e1013801. https:\/\/doi.org\/10.1371\/journal.pcbi.1013801.","DOI":"10.1371\/journal.pcbi.1013801"},{"issue":"5","key":"957_CR38","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.3390\/ijms24054422","volume":"24","author":"HT Tzeng","year":"2023","unstructured":"Tzeng HT, Huang YJ. Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity. IJMS. 2023;24(5):4422. https:\/\/doi.org\/10.3390\/ijms24054422.","journal-title":"IJMS"},{"key":"957_CR39","doi-asserted-by":"publisher","first-page":"1731338","DOI":"10.3389\/fimmu.2025.1731338","volume":"16","author":"D Aguilar-Cazares","year":"2026","unstructured":"Aguilar-Cazares D, Perez-Medina M, Benito-Lopez JJ, Galicia-Velasco M, Meneses-Flores M, Camarena A, et al. The tumor microenvironment: adding pieces to the puzzle. Front Immunol. 2026;16:1731338. https:\/\/doi.org\/10.3389\/fimmu.2025.1731338.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12885-024-11875-w","volume":"24","author":"JS Liu","year":"2024","unstructured":"Liu JS, Cai YX, He YZ, Xu J, Tian SF, Li ZQ. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC. BMC Cancer. 2024;24(1):123. https:\/\/doi.org\/10.1186\/s12885-024-11875-w.","journal-title":"BMC Cancer"},{"key":"957_CR41","doi-asserted-by":"publisher","unstructured":"Yuan Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb Perspect Med. 2016;6(8):a026583. https:\/\/doi.org\/10.1101\/cshperspect.a026583.","DOI":"10.1101\/cshperspect.a026583"},{"issue":"3","key":"957_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.annonc.2025.10.1239","volume":"37","author":"BP Keenan","year":"2026","unstructured":"Keenan BP, Yadav M, Ansstas G, Fabrizio D, Murugesan K, Montesion M, et al. Intratumoral heterogeneity and immunotherapy resistance: clinical implications. Ann Oncol. 2026;37(3):314\u201328. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.1239.","journal-title":"Ann Oncol"},{"key":"957_CR43","doi-asserted-by":"publisher","unstructured":"Cheng R, Santos HA. Smart nanoparticle-based platforms for regulating tumor microenvironment and cancer immunotherapy. Adv Healthcare Mater. 2023;12(8):e2202063. https:\/\/doi.org\/10.1002\/adhm.202202063.","DOI":"10.1002\/adhm.202202063"},{"key":"957_CR44","doi-asserted-by":"publisher","unstructured":"Bo\u017cyk A, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Tumor microenvironment-a short review of cellular and interaction diversity. Biol (Basel). 2022;11(6). https:\/\/doi.org\/10.3390\/biology11060929.","DOI":"10.3390\/biology11060929"},{"issue":"1","key":"957_CR45","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1038\/s41467-023-41518-w","volume":"14","author":"S Mayer","year":"2023","unstructured":"Mayer S, Milo T, Isaacson A, Halperin C, Miyara S, Stein Y, et al. The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. Nat Commun. 2023;14(1):5810. https:\/\/doi.org\/10.1038\/s41467-023-41518-w.","journal-title":"Nat Commun"},{"issue":"8","key":"957_CR46","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ccell.2021.07.009","volume":"39","author":"D Pe\u2019er","year":"2021","unstructured":"Pe\u2019er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D. Tumor heterogeneity. Cancer Cell. 2021;39(8):1015\u201317. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.009.","journal-title":"Cancer Cell"},{"key":"957_CR47","doi-asserted-by":"publisher","first-page":"757024","DOI":"10.3389\/fmolb.2021.757024","volume":"8","author":"D Pan","year":"2021","unstructured":"Pan D, Jia D. Application of single-cell multi-omics in Dissecting cancer cell plasticity and tumor heterogeneity. Front Mol Biosci. 2021;8:757024. https:\/\/doi.org\/10.3389\/fmolb.2021.757024.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"957_CR48","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","volume":"14","author":"A Janesick","year":"2023","unstructured":"Janesick A, Shelansky R, Gottscho AD, Wagner F, Williams SR, Rouault M, et al. High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis. Nat Commun. 2023;14(1):8353. https:\/\/doi.org\/10.1038\/s41467-023-43458-x.","journal-title":"Nat Commun"},{"issue":"7","key":"957_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332. https:\/\/doi.org\/10.1038\/s12276-023-01013-0.","journal-title":"Exp Mol Med"},{"issue":"3","key":"957_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"957_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.trecan.2025.05.003","volume":"11","author":"JL Chitty","year":"2025","unstructured":"Chitty JL, Cox TR. The extracellular matrix in cancer: from understanding to targeting. Trends Cancer. 2025;11(9):839\u201349. https:\/\/doi.org\/10.1016\/j.trecan.2025.05.003.","journal-title":"Trends Cancer"},{"key":"957_CR52","doi-asserted-by":"publisher","first-page":"864302","DOI":"10.3389\/fmolb.2022.864302","volume":"9","author":"JE Fromme","year":"2022","unstructured":"Fromme JE, Zigrino P. The role of extracellular matrix remodeling in skin tumor progression and therapeutic resistance. Front Mol Biosci. 2022;9:864302. https:\/\/doi.org\/10.3389\/fmolb.2022.864302.","journal-title":"Front Mol Biosci"},{"key":"957_CR53","doi-asserted-by":"publisher","unstructured":"Yang D, Guo P, He T, Powell CA. Role of endothelial cells in tumor microenvironment. Clin Transl Med. 2021;11(6):e450. https:\/\/doi.org\/10.1002\/ctm2.450.","DOI":"10.1002\/ctm2.450"},{"issue":"1","key":"957_CR54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Sig Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Sig Transduct Target Ther"},{"key":"957_CR55","doi-asserted-by":"publisher","unstructured":"Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm (2020). 2023;4(5):e343. https:\/\/doi.org\/10.1002\/mco2.343.","DOI":"10.1002\/mco2.343"},{"issue":"9","key":"957_CR56","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bl\u00e9riot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20(9):983\u201392. https:\/\/doi.org\/10.1038\/s41423-023-01061-6.","journal-title":"Cell Mol Immunol"},{"key":"957_CR57","doi-asserted-by":"publisher","first-page":"1157291","DOI":"10.3389\/fimmu.2023.1157291","volume":"14","author":"L Xiao","year":"2023","unstructured":"Xiao L, Wang Q, Peng H. Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy. Front Immunol. 2023;14:1157291. https:\/\/doi.org\/10.3389\/fimmu.2023.1157291.","journal-title":"Front Immunol"},{"issue":"11","key":"957_CR58","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1083\/jcb.201704053","volume":"216","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 2017;216(11):3799\u2013816. https:\/\/doi.org\/10.1083\/jcb.201704053.","journal-title":"J Cell Biol"},{"key":"957_CR59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts Build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7:60. https:\/\/doi.org\/10.3389\/fcell.2019.00060.","journal-title":"Front. Cell Dev. Biol"},{"issue":"11","key":"957_CR60","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1084\/jem.20151193","volume":"213","author":"R Afik","year":"2016","unstructured":"Afik R, Zigmond E, Vugman M, Klepfish M, Shimshoni E, Pasmanik-Chor M, et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix. J Exp Med. 2016;213(11):2315\u201331. https:\/\/doi.org\/10.1084\/jem.20151193.","journal-title":"J Exp Med"},{"issue":"13","key":"957_CR61","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1016\/j.celrep.2017.12.011","volume":"21","author":"DH Madsen","year":"2017","unstructured":"Madsen DH, J\u00fcrgensen HJ, Siersb\u00e6k MS, Kuczek DE, Grey Cloud L, Liu S, et al. Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Rep. 2017;21(13):3662\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.011.","journal-title":"Cell Rep"},{"issue":"6409","key":"957_CR62","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1126\/science.aao4227","volume":"361","author":"J Albrengues","year":"2018","unstructured":"Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409):6409. https:\/\/doi.org\/10.1126\/science.aao4227.","journal-title":"Science"},{"issue":"1","key":"957_CR63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersb\u00e6k MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68. https:\/\/doi.org\/10.1186\/s40425-019-0556-6.","journal-title":"J Immunother Cancer"},{"key":"957_CR64","doi-asserted-by":"publisher","unstructured":"Fuller AM, Pruitt HC, Liu Y, Irizarry-Negron VM, Pan H, Song H, et al. Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment. J Clin Investigation. 2024;134(11). https:\/\/doi.org\/10.1172\/JCI167826.","DOI":"10.1172\/JCI167826"},{"key":"957_CR65","doi-asserted-by":"publisher","unstructured":"Bunting\u2009MD, Vyas M, Requesens M, Langenbucher A, Schiferle EB, Manguso RT, et al. Extracellular\u2009 matrix proteins\u2009 regulate NK cell function\u2009 in peripheral tissues.\u2009 Sci Adv. 2022;8(11):eabk 3327. https:\/\/doi.org\/10.1126\/sciadv.abk3327.","DOI":"10.1126\/sciadv.abk3327"},{"issue":"9","key":"957_CR66","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.imbio.2011.12.006","volume":"217","author":"RI Cordo Russo","year":"2012","unstructured":"Cordo Russo RI, Ernst G, Lompard\u00eda, Blanco G, \u00c1lvarez \u00c9, Garcia MG, et al. Increased hyaluronan levels and decreased dendritic cell activation are associated with tumor invasion in murine lymphoma cell lines. Immunobiology. 2012;217(9):842\u201350. https:\/\/doi.org\/10.1016\/j.imbio.2011.12.006.","journal-title":"Immunobiology"},{"key":"957_CR67","doi-asserted-by":"publisher","unstructured":"Rizzo M, Bayo J, Piccioni F, Malvicini M, Fiore E, Peixoto E, et al. Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction. PLoS ONE. 2014;9(9):e107944. https:\/\/doi.org\/10.1371\/journal.pone.0107944.","DOI":"10.1371\/journal.pone.0107944"},{"issue":"1","key":"957_CR68","doi-asserted-by":"publisher","first-page":"28039","DOI":"10.1038\/srep28039","volume":"6","author":"N Maishi","year":"2016","unstructured":"Maishi N, Ohba Y, Akiyama K, Ohga N, Hamada J, Nagao-Kitamoto H, et al. Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Sci Rep. 2016;6(1):28039. https:\/\/doi.org\/10.1038\/srep28039.","journal-title":"Sci Rep"},{"issue":"6","key":"957_CR69","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/bjc.2012.59","volume":"106","author":"K Yamamoto","year":"2012","unstructured":"Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, et al. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer. 2012;106(6):1214\u201323. https:\/\/doi.org\/10.1038\/bjc.2012.59.","journal-title":"Br J Cancer"},{"key":"957_CR70","doi-asserted-by":"publisher","unstructured":"Vymola P, Garcia-Borja E, Cervenka J, Balaziova E, Vymolova B, Veprkova J, et al. Fibrillar extracellular matrix produced by pericyte-like cells facilitates glioma cell dissemination. Brain Pathol. 2024;34(6):e13265. https:\/\/doi.org\/10.1111\/bpa.13265.","DOI":"10.1111\/bpa.13265"},{"issue":"1","key":"957_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/0115701611365339250213101338","volume":"24","author":"J Tan","year":"2026","unstructured":"Tan J, Yu Z, Pi R, Lin Y, Wang W, Chen M, et al. Tumor-associated Pericytes: tumorigenicity and targeting for cancer therapy. CVP. 2026;24(1):3\u201319. https:\/\/doi.org\/10.2174\/0115701611365339250213101338.","journal-title":"CVP"},{"issue":"4","key":"957_CR72","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5483\/BMBRep.2018.51.4.185","volume":"51","author":"EJ Lim","year":"2018","unstructured":"Lim EJ, Suh Y, Kim S, Kang SG, Lee SJ. Force-mediated proinvasive matrix remodeling driven by tumor-associated mesenchymal stem-like cells in glioblastoma. BMB Rep. 2018;51(4):182\u201387. https:\/\/doi.org\/10.5483\/BMBRep.2018.51.4.185.","journal-title":"BMB Rep"},{"key":"957_CR73","doi-asserted-by":"publisher","unstructured":"Ghosh D, Mejia Pena C, Quach N, Xuan B, Lee AH, Dawson MR. Senescent mesenchymal stem cells remodel extracellular matrix driving breast cancer cells to a more-invasive phenotype. J Cell Sci. 2020;133(2). https:\/\/doi.org\/10.1242\/jcs.232470.","DOI":"10.1242\/jcs.232470"},{"issue":"5","key":"957_CR74","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI23424","volume":"115","author":"P Iyengar","year":"2005","unstructured":"Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor\/stroma microenvironment. J Clin Invest. 2005;115(5):1163\u201376. https:\/\/doi.org\/10.1172\/JCI23424.","journal-title":"J. Clin. Invest"},{"issue":"11","key":"957_CR75","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1172\/JCI63930","volume":"122","author":"J Park","year":"2012","unstructured":"Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Invest. 2012;122(11):4243\u201356. https:\/\/doi.org\/10.1172\/JCI63930.","journal-title":"J. Clin. Invest"},{"issue":"1","key":"957_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbcan.2009.02.001","volume":"1796","author":"S Maltby","year":"2009","unstructured":"Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim et Biophys Acta (BBA) - Rev Cancer. 2009;1796(1):19\u201326. https:\/\/doi.org\/10.1016\/j.bbcan.2009.02.001.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"8","key":"957_CR77","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3390\/cancers14081947","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Manouchehri Doulabi E, Herre M, Cedervall J, Qiao Q, Miao Z, et al. Platelet-derived PDGFB promotes recruitment of cancer-associated fibroblasts, deposition of extracellular matrix and Tgf\u03b2 signaling in the tumor microenvironment. Cancers (Basel). 2022;14(8):1947. https:\/\/doi.org\/10.3390\/cancers14081947.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"957_CR78","doi-asserted-by":"publisher","first-page":"102416","DOI":"10.1016\/j.xcrm.2025.102416","volume":"6","author":"F Lodi","year":"2025","unstructured":"Lodi F, Vanmassenhove S, Chen D, Boeckx B, Ferreira Maciel L, Peeters F, et al. Decoding tumor heterogeneity: a spatially informed pan-cancer analysis of the tumor microenvironment. Cell Rep. Med. 2025;6(10):102416. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102416.","journal-title":"Cell Rep. Med"},{"issue":"3","key":"957_CR79","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"957_CR80","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. https:\/\/doi.org\/10.1038\/s41467-020-18794-x.","journal-title":"Nat Commun"},{"issue":"3","key":"957_CR81","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","volume":"125","author":"AL Magnussen","year":"2021","unstructured":"Magnussen AL, Mills IG. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer. 2021;125(3):324\u201336. https:\/\/doi.org\/10.1038\/s41416-021-01330-z.","journal-title":"Br J Cancer"},{"issue":"5","key":"957_CR82","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307. https:\/\/doi.org\/10.1038\/s41419-024-06697-4.","journal-title":"Cell Death Dis"},{"issue":"1","key":"957_CR83","doi-asserted-by":"publisher","first-page":"151527","DOI":"10.1016\/j.ejcb.2025.151527","volume":"105","author":"DL Boaru","year":"2026","unstructured":"Boaru DL, De Leon-Oliva D, Fraile-Martinez O, De Castro-Martinez P, Garcia-Montero C, Ferrara-Coppola C, et al. The role of the LOX family in cancer. Eur J Cell Biol. 2026;105(1):151527. https:\/\/doi.org\/10.1016\/j.ejcb.2025.151527.","journal-title":"Eur J Cell Biol"},{"key":"957_CR84","doi-asserted-by":"publisher","first-page":"1672601","DOI":"10.3389\/fimmu.2025.1672601","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Han W, Zhang M, Yi Y, Long M. Targeting tumor microenvironmental barriers to enhance immunogenic cell death in solid tumors. Front Immunol. 2025;16:1672601. https:\/\/doi.org\/10.3389\/fimmu.2025.1672601.","journal-title":"Front Immunol"},{"issue":"11","key":"957_CR85","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55(11):2308\u201319. https:\/\/doi.org\/10.1038\/s12276-023-01114-w.","journal-title":"Exp Mol Med"},{"issue":"1","key":"957_CR86","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12951-025-03815-y","volume":"23","author":"P Gong","year":"2025","unstructured":"Gong P, Wang F, Hua Y, Ying J, Chen J, Qiao Y. Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy. J Nanobiotechnol. 2025;23(1):733. https:\/\/doi.org\/10.1186\/s12951-025-03815-y.","journal-title":"J Nanobiotechnol"},{"key":"957_CR87","doi-asserted-by":"publisher","first-page":"1276694","DOI":"10.3389\/fimmu.2023.1276694","volume":"14","author":"P Yu","year":"2023","unstructured":"Yu P, Wang Y, Yuan D, Sun Y, Qin S, Li T. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer. Front Immunol. 2023;14:1276694. https:\/\/doi.org\/10.3389\/fimmu.2023.1276694.","journal-title":"Front Immunol"},{"issue":"21","key":"957_CR88","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.3390\/cancers17213411","volume":"17","author":"F Zhou","year":"2025","unstructured":"Zhou F, Mu G, Bi H, Chen L, Zha Z, Jin Y, et al. Targeted hyaluronan degradation enhanced tumor growth inhibition in gastrointestinal cancer models. Cancers (Basel). 2025;17(21):3411. https:\/\/doi.org\/10.3390\/cancers17213411.","journal-title":"Cancers (Basel)"},{"key":"957_CR89","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.neo.2022.100793","volume":"30","author":"T Seki","year":"2022","unstructured":"Seki T, Saida Y, Kishimoto S, Lee J, Otowa Y, Yamamoto K, et al. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia. 2022;30:100793. https:\/\/doi.org\/10.1016\/j.neo.2022.100793.","journal-title":"Neoplasia"},{"issue":"1","key":"957_CR90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-025-00691-y","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang F, Qian Z, Jiang Y, Wu D, Liu L, et al. Targeting collagen to optimize cancer immunotherapy. Exp Hematol Oncol. 2025;14(1):101. https:\/\/doi.org\/10.1186\/s40164-025-00691-y.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"957_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1741-7015-6-11","volume":"6","author":"PP Provenzano","year":"2008","unstructured":"Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6(1):11. https:\/\/doi.org\/10.1186\/1741-7015-6-11.","journal-title":"BMC Med"},{"issue":"5","key":"957_CR92","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891\u2013906. https:\/\/doi.org\/10.1016\/j.cell.2009.10.027.","journal-title":"Cell"},{"issue":"5","key":"957_CR93","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.ajpath.2015.01.029","volume":"185","author":"BK Brisson","year":"2015","unstructured":"Brisson BK, Mauldin EA, Lei W, Vogel LK, Power AM, Lo A, et al. Type III collagen directs stromal organization and limits metastasis in a murine model of breast cancer. Am J Pathol. 2015;185(5):1471\u201386. https:\/\/doi.org\/10.1016\/j.ajpath.2015.01.029.","journal-title":"Am J Pathol"},{"issue":"1","key":"957_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s43018-021-00291-9","volume":"3","author":"JS Di Martino","year":"2021","unstructured":"Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2021;3(1):90\u2013107. https:\/\/doi.org\/10.1038\/s43018-021-00291-9.","journal-title":"Nat Cancer"},{"issue":"5","key":"957_CR95","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/carcin\/20.5.749","volume":"20","author":"ZS Zeng","year":"1999","unstructured":"Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20(5):749\u201355. https:\/\/doi.org\/10.1093\/carcin\/20.5.749.","journal-title":"Carcinogenesis"},{"issue":"6","key":"957_CR96","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/emmm.201202006","volume":"5","author":"J Park","year":"2013","unstructured":"Park J, Morley TS, Scherer PE. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med. 2013;5(6):935\u201348. https:\/\/doi.org\/10.1002\/emmm.201202006.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"957_CR97","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3727\/096504011X13079697132925","volume":"19","author":"H Sil","year":"2011","unstructured":"Sil H, Sen T, Chatterjee A. Fibronectin-integrin (\u03b15\u03b21) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol Res. 2011;19(7):335\u201348. https:\/\/doi.org\/10.3727\/096504011X13079697132925.","journal-title":"Oncol Res"},{"issue":"5","key":"957_CR98","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/sj.bjc.6604252","volume":"98","author":"Y Baba","year":"2008","unstructured":"Baba Y, Iyama KI, Hirashima K, Nagai Y, Yoshida N, Hayashi N, et al. Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation. Br J Cancer. 2008;98(5):974\u201380. https:\/\/doi.org\/10.1038\/sj.bjc.6604252.","journal-title":"Br J Cancer"},{"issue":"1","key":"957_CR99","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajpath.2010.11.028","volume":"178","author":"BG Kim","year":"2011","unstructured":"Kim BG, An HJ, Kang S, Choi YP, Gao MQ, Park H, et al. Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer. Am J Pathol. 2011;178(1):373\u201381. https:\/\/doi.org\/10.1016\/j.ajpath.2010.11.028.","journal-title":"Am J Pathol"},{"issue":"22","key":"957_CR100","doi-asserted-by":"publisher","first-page":"16667","DOI":"10.1074\/jbc.M702078200","volume":"282","author":"SR Hamilton","year":"2007","unstructured":"Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, et al. The hyaluronan receptors CD44 and rhamm (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells. J Biol Chem. 2007;282(22):16667\u201380. https:\/\/doi.org\/10.1074\/jbc.M702078200.","journal-title":"J Biol Chem"},{"issue":"1","key":"957_CR101","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ccr.2014.06.003","volume":"26","author":"VP Chauhan","year":"2014","unstructured":"Chauhan VP, Boucher Y, Ferrone CR, Roberge S, Martin JD, Stylianopoulos T, et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell. 2014;26(1):14\u201315. https:\/\/doi.org\/10.1016\/j.ccr.2014.06.003.","journal-title":"Cancer Cell"},{"issue":"7","key":"957_CR102","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nm.2379","volume":"17","author":"T Oskarsson","year":"2011","unstructured":"Oskarsson T, Acharyya S, Zhang XH-F, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7):867\u201374. https:\/\/doi.org\/10.1038\/nm.2379.","journal-title":"Nat Med"},{"issue":"4","key":"957_CR103","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1535-6108(04)00081-9","volume":"5","author":"S Bao","year":"2004","unstructured":"Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt\/PKB pathway. Cancer Cell. 2004;5(4):329\u201339. https:\/\/doi.org\/10.1016\/S1535-6108(04)00081-9.","journal-title":"Cancer Cell"},{"issue":"4","key":"957_CR104","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/path.4747","volume":"239","author":"Z Wang","year":"2016","unstructured":"Wang Z, Xiong S, Mao Y, Chen M, Ma X, Zhou X, et al. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. The J Pathol. 2016;239(4):484\u201395. https:\/\/doi.org\/10.1002\/path.4747.","journal-title":"The J Pathol"},{"issue":"4","key":"957_CR105","first-page":"605","volume":"3","author":"H Singhal","year":"1997","unstructured":"Singhal H, Bautista DS, Tonkin KS, O\u2019Malley FP, Tuck AB, Chambers AF, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997;3(4):605\u201311.","journal-title":"Clin Cancer Res"},{"key":"957_CR106","doi-asserted-by":"publisher","unstructured":"Jia R, Liang Y, Chen R, Liu G, Wang H, Tang M, et al. Osteopontin facilitates tumor metastasis by regulating epithelial\u2013mesenchymal plasticity. Cell Death Dis. 2016;7(12):e 2564. https:\/\/doi.org\/10.1038\/cddis.2016.422.","DOI":"10.1038\/cddis.2016.422"},{"issue":"6","key":"957_CR107","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-11-2905","volume":"72","author":"D Gao","year":"2012","unstructured":"Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012;72(6):1384\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2905.","journal-title":"Cancer Res"},{"key":"957_CR108","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fonc.2019.00577","volume":"9","author":"DC Dos Reis","year":"2019","unstructured":"Dos Reis DC, Damasceno KA, de Campos Cb, Veloso ES, P\u00eagas, Kraemer LR, et al. Versican and tumor-associated macrophages promotes tumor progression and metastasis in canine and murine models of breast carcinoma. Front Oncol. 2019;9:577. https:\/\/doi.org\/10.3389\/fonc.2019.00577.","journal-title":"Front Oncol"},{"issue":"2","key":"957_CR109","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1172\/JCI846","volume":"101","author":"DK Moscatello","year":"1998","unstructured":"Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest. 1998;101(2):406\u201312. https:\/\/doi.org\/10.1172\/JCI846.","journal-title":"J. Clin. Invest"},{"issue":"6","key":"957_CR110","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1074\/jbc.273.6.3121","volume":"273","author":"S Patel","year":"1998","unstructured":"Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP. Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells. J Biol Chem. 1998;273(6):3121\u201324. https:\/\/doi.org\/10.1074\/jbc.273.6.3121.","journal-title":"J Biol Chem"},{"issue":"1","key":"957_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13058-021-01423-w","volume":"23","author":"L Cong","year":"2021","unstructured":"Cong L, Maishi N, Annan DA, Young MF, Morimoto H, Morimoto M, et al. Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy. Breast Cancer Res. 2021;23(1):51. https:\/\/doi.org\/10.1186\/s13058-021-01423-w.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"957_CR112","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1172\/JCI3793","volume":"102","author":"B Sharma","year":"1998","unstructured":"Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102(8):1599\u2013608. https:\/\/doi.org\/10.1172\/JCI3793.","journal-title":"J. Clin. Invest"},{"issue":"11","key":"957_CR113","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1177\/002215540305101101","volume":"51","author":"X Jiang","year":"2003","unstructured":"Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem. 2003;51(11):1393\u2013410. https:\/\/doi.org\/10.1177\/002215540305101101.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"957_CR114","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3892\/ol.2020.12313","volume":"21","author":"R Jagroop","year":"2020","unstructured":"Jagroop R, Martin CJ, Moorehead RA. Nidogen 1 regulates proliferation and migration\/invasion in murine claudin\u2011low mammary tumor cells. Oncol Lett. 2020;21(1):52. https:\/\/doi.org\/10.3892\/ol.2020.12313.","journal-title":"Oncol Lett"},{"issue":"22","key":"957_CR115","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.3390\/cancers15225316","volume":"15","author":"M Rokavec","year":"2023","unstructured":"Rokavec M, Jaeckel S, Hermeking H. Nidogen-1\/NID1 function and regulation during progression and metastasis of colorectal cancer. Cancers (Basel). 2023;15(22):5316. https:\/\/doi.org\/10.3390\/cancers15225316.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"957_CR116","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1242\/jcs.01613","volume":"118","author":"A Robinet","year":"2005","unstructured":"Robinet A, Fahem A, Cauchard JH, Huet E, Vincent L, Lorimier S, et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci. 2005;118(2):343\u201356. https:\/\/doi.org\/10.1242\/jcs.01613.","journal-title":"J Cell Sci"},{"issue":"10","key":"957_CR117","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1084\/jem.20030202","volume":"198","author":"S Sangaletti","year":"2003","unstructured":"Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med. 2003;198(10):1475\u201385. https:\/\/doi.org\/10.1084\/jem.20030202.","journal-title":"J Exp Med"},{"issue":"1\u20132","key":"957_CR118","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1242\/dmm.003228","volume":"3","author":"SA Arnold","year":"2010","unstructured":"Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, et al. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Disease Model Mechanisms. 2010;3(1\u20132):57\u201372. https:\/\/doi.org\/10.1242\/dmm.003228.","journal-title":"Disease Model Mechanisms"},{"issue":"6","key":"957_CR119","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1158\/0008-5472.CAN-12-2233","volume":"73","author":"TR Cox","year":"2013","unstructured":"Cox TR, Bird D, Baker AM, Barker HE, Ho MW-Y, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73(6):1721\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2233.","journal-title":"Cancer Res"},{"issue":"4","key":"957_CR120","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00432-001-0320-3","volume":"128","author":"E Hrabec","year":"2002","unstructured":"Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer ResearchClin Oncol. 2002;128(4):197\u2013204. https:\/\/doi.org\/10.1007\/s00432-001-0320-3.","journal-title":"J Cancer ResearchClin Oncol"},{"issue":"7","key":"957_CR121","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/10525","volume":"5","author":"MD Hulett","year":"1999","unstructured":"Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 1999;5(7):803\u201309. https:\/\/doi.org\/10.1038\/10525.","journal-title":"Nat Med"},{"issue":"2","key":"957_CR122","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/scbi.2001.0420","volume":"12","author":"I Vlodavsky","year":"2002","unstructured":"Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol. 2002;12(2):121\u201329. https:\/\/doi.org\/10.1006\/scbi.2001.0420.","journal-title":"Semin Cancer Biol"},{"key":"957_CR123","doi-asserted-by":"publisher","unstructured":"Zhang T, Gao P, Sun L. Targeting metabolic reprogramming in tumor: from mechanisms to precision immunotherapies. MedComm \u2013 Oncol. 2025;4(4):e70045. https:\/\/doi.org\/10.1002\/mog2.70045.","DOI":"10.1002\/mog2.70045"},{"key":"957_CR124","doi-asserted-by":"publisher","first-page":"217076","DOI":"10.1016\/j.canlet.2024.217076","volume":"597","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhao Y, Song H, Li Y, Liu Z, Ye Z, et al. Metabolic reprogramming in tumor immune microenvironment: impact on immune cell function and therapeutic implications. Cancer Lett. 2024;597:217076. https:\/\/doi.org\/10.1016\/j.canlet.2024.217076.","journal-title":"Cancer Lett"},{"issue":"1","key":"957_CR125","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12967-025-07272-x","volume":"23","author":"Z Dong","year":"2025","unstructured":"Dong Z, Yuan Z, Jin T, Gao C, Wang X, Xu F. Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy. J Transl Med. 2025;23(1):1239. https:\/\/doi.org\/10.1186\/s12967-025-07272-x.","journal-title":"J Transl Med"},{"key":"957_CR126","doi-asserted-by":"publisher","first-page":"218038","DOI":"10.1016\/j.canlet.2025.218038","volume":"633","author":"Z Wang","year":"2025","unstructured":"Wang Z, Gu Z, Mo W, Zhang H. Lactate metabolic checkpoint in immuno-oncology: mechanisms and therapeutic implications. Cancer Lett. 2025;633:218038. https:\/\/doi.org\/10.1016\/j.canlet.2025.218038.","journal-title":"Cancer Lett"},{"key":"957_CR127","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303. https:\/\/doi.org\/10.3389\/fimmu.2025.1563303.","journal-title":"Front Immunol"},{"issue":"11","key":"957_CR128","doi-asserted-by":"publisher","first-page":"116463","DOI":"10.1016\/j.celrep.2025.116463","volume":"44","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Tong H, Sun H, Liao H, Li Q, et al. Metabolic regulation of immunity in the tumor microenvironment. Cell Rep. 2025;44(11):116463. https:\/\/doi.org\/10.1016\/j.celrep.2025.116463.","journal-title":"Cell Rep"},{"issue":"8","key":"957_CR129","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A phase I dose-escalation study of AZD3965, an Oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29(8):1429\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2263.","journal-title":"Clin Cancer Res"},{"key":"957_CR130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3115","volume-title":"Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL)","author":"SE Halford","year":"2021","unstructured":"Halford SE, Walter H, McKay P, Townsend W, Linton K, Heinzmann K, et al. Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Wolters Kluwer Health; 2021."},{"issue":"4","key":"957_CR131","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55(4):706\u201315. https:\/\/doi.org\/10.1038\/s12276-023-00971-9.","journal-title":"Exp Mol Med"},{"issue":"2","key":"957_CR132","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3892\/ijo.2020.5158","volume":"58","author":"S Pan","year":"2020","unstructured":"Pan S, Fan M, Liu Z, Li X, Wang H. Serine, glycine and one\u2011carbon metabolism in cancer (review). Int J Oncol. 2020;58(2):158\u201370. https:\/\/doi.org\/10.3892\/ijo.2020.5158.","journal-title":"Int J Oncol"},{"issue":"1","key":"957_CR133","doi-asserted-by":"publisher","first-page":"37028","DOI":"10.1038\/s41598-025-20528-2","volume":"15","author":"M Spada","year":"2025","unstructured":"Spada M, Piras C, Leoni VP, Casula M, Simbula G, Noto A, et al. Glutaminase inhibitor CB-839 causes metabolic adjustments in colorectal cancer cells. Sci Rep. 2025;15(1):37028. https:\/\/doi.org\/10.1038\/s41598-025-20528-2.","journal-title":"Sci Rep"},{"issue":"5","key":"957_CR134","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"M Gouda","year":"2025","unstructured":"Gouda M, Voss M, Tawbi H, Gordon M, Tykodi S, Lam E, et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025;10(5):104536. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536.","journal-title":"ESMO Open"},{"issue":"6","key":"957_CR135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","volume":"45","author":"AR Terry","year":"2024","unstructured":"Terry AR, Hay N. Emerging targets in lipid metabolism for cancer therapy. Trends Pharmacological Sci. 2024;45(6):537\u201351. https:\/\/doi.org\/10.1016\/j.tips.2024.04.007.","journal-title":"Trends Pharmacological Sci"},{"key":"957_CR136","doi-asserted-by":"publisher","first-page":"1728354","DOI":"10.3389\/fimmu.2025.1728354","volume":"16","author":"W Liu","year":"2025","unstructured":"Liu W, Wang Z, Li Z, Li S, Shi X, Xu Y, et al. Lipid metabolic reprogramming in the tumor microenvironment and its mechanistic role in immunosuppressive cells. Front Immunol. 2025;16:1728354. https:\/\/doi.org\/10.3389\/fimmu.2025.1728354.","journal-title":"Front Immunol"},{"issue":"3","key":"957_CR137","doi-asserted-by":"publisher","first-page":"101772","DOI":"10.1016\/j.gendis.2025.101772","volume":"13","author":"W Zhang","year":"2026","unstructured":"Zhang W, Wang P, Yuan G, Liu F, Jin G, Zhang J. Fatty acid metabolic reprogramming in the tumor microenvironment: unraveling mechanisms and therapeutic prospects. Genes Dis. 2026;13(3):101772. https:\/\/doi.org\/10.1016\/j.gendis.2025.101772.","journal-title":"Genes Dis"},{"issue":"1","key":"957_CR138","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s12672-025-04001-0","volume":"16","author":"X Yin","year":"2025","unstructured":"Yin X, Yang Y, Liu S. Cancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints. Discov Oncol. 2025;16(1):2153. https:\/\/doi.org\/10.1007\/s12672-025-04001-0.","journal-title":"Discov Oncol"},{"issue":"7","key":"957_CR139","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1021\/acs.jmedchem.4c02151","volume":"68","author":"C Bi","year":"2025","unstructured":"Bi C, Patel JS, Liang SH. Development of CD73 inhibitors in tumor immunotherapy and opportunities in imaging and combination therapy. J Med Chem. 2025;68(7):6860\u201369. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02151.","journal-title":"J Med Chem"},{"key":"957_CR140","doi-asserted-by":"publisher","first-page":"1742855","DOI":"10.3389\/fimmu.2025.1742855","volume":"16","author":"M Li","year":"2026","unstructured":"Li M, Wang T, Zhang Z, Dongye Y. Metabolic reprogramming in the post-metastatic tumor microenvironment: multi-omics insights into determinants of immunotherapy response. Front Immunol. 2026;16:1742855. https:\/\/doi.org\/10.3389\/fimmu.2025.1742855.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR141","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-026-00744-w","volume":"15","author":"F Heydari","year":"2026","unstructured":"Heydari F, Hamblin MR, Naghinezhad J. Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation. Exp Hematol Oncol. 2026;15(1):13. https:\/\/doi.org\/10.1186\/s40164-026-00744-w.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"957_CR142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11883-026-01394-3","volume":"28","author":"F Heydari","year":"2026","unstructured":"Heydari F, Hamblin MR, Naghinezhad J. From inflammation to targeted therapy: leveraging neutrophil, platelet, RBC, and macrophage biology for nanocarrier in Atherosclerosis. Curr Atheroscler Rep. 2026;28(1):26. https:\/\/doi.org\/10.1007\/s11883-026-01394-3.","journal-title":"Curr Atheroscler Rep"},{"issue":"13","key":"957_CR143","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","volume":"23","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, O\u2019Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, et al. First-in-human phase I study of the Oral inhibitor of indoleamine 2, 3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23(13):3269\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2272.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"957_CR144","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","volume":"6","author":"A Nayak-Kapoor","year":"2018","unstructured":"Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, et al. Phase Ia study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer. 2018;6(1):61. https:\/\/doi.org\/10.1186\/s40425-018-0351-9.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"957_CR145","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1200\/JCO.2009.26.7765","volume":"28","author":"ES Glazer","year":"2010","unstructured":"Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. JCO. 2010;28(13):2220\u201326. https:\/\/doi.org\/10.1200\/JCO.2009.26.7765.","journal-title":"JCO"},{"issue":"1","key":"957_CR146","doi-asserted-by":"publisher","first-page":"1943253","DOI":"10.1080\/2162402X.2021.1943253","volume":"10","author":"KY Chang","year":"2021","unstructured":"Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, et al. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus pembrolizumab in advanced solid cancers. Oncoimmunology. 2021;10(1):1943253. https:\/\/doi.org\/10.1080\/2162402X.2021.1943253.","journal-title":"Oncoimmunology"},{"key":"957_CR147","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.trsl.2019.12.005","volume":"217","author":"G Agnello","year":"2020","unstructured":"Agnello G, Alters SE, Rowlinson SW. Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1. Transl Res. 2020;217:11\u201322. https:\/\/doi.org\/10.1016\/j.trsl.2019.12.005.","journal-title":"Transl Res"},{"issue":"18","key":"957_CR148","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, et al. A phase I dose-escalation and expansion study of Telaglenastat in patients with advanced or metastatic solid tumors. Clin Cancer Res. 2021;27(18):4994\u20135003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1204.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"957_CR149","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, et al. Telaglenastat plus Cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an Open-label phase I trial. Clin Cancer Res. 2022;28(8):1540\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2972.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"957_CR150","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","volume":"20","author":"S Varghese","year":"2021","unstructured":"Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, et al. The glutaminase inhibitor CB-839 (Telaglenastat) enhances the antimelanoma activity of T-Cell\u2013mediated immunotherapies. Mol Cancer Ther. 2021;20(3):500\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0430.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"957_CR151","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1073\/pnas.1521548113","volume":"113","author":"E Mullarky","year":"2016","unstructured":"Mullarky E, Lucki NC, Beheshti Zavareh R, Anglin JL, Gomes AP, Nicolay BN, et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci USA. 2016;113(7):1778\u201383. https:\/\/doi.org\/10.1073\/pnas.1521548113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"957_CR152","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1158\/0008-5472.CAN-23-1788","volume":"84","author":"S Saha","year":"2024","unstructured":"Saha S, Ghosh M, Li J, Wen A, Galluzzi L, Martinez LA, et al. Serine depletion promotes antitumor immunity by activating mitochondrial DNA-Mediated cGAS-STING signaling. Cancer Res. 2024;84(16):2645\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1788.","journal-title":"Cancer Res"},{"issue":"20","key":"957_CR153","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.3390\/cancers14205060","volume":"14","author":"M Van de Gucht","year":"2022","unstructured":"Van de Gucht M, Dufait I, Kerkhove L, Corbet C, de Mey S, Jiang H, et al. Inhibition of phosphoglycerate dehydrogenase radiosensitizes human colorectal cancer cells under hypoxic conditions. Cancers (Basel). 2022;14(20):5060. https:\/\/doi.org\/10.3390\/cancers14205060.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"957_CR154","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","volume":"5","author":"JNR Gnanaprakasam","year":"2023","unstructured":"Gnanaprakasam JNR, Kushwaha B, Liu L, Chen X, Kang S, Wang T, et al. Asparagine restriction enhances CD8+ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response. Nat Metab. 2023;5(8):1423\u201339. https:\/\/doi.org\/10.1038\/s42255-023-00856-1.","journal-title":"Nat Metab"},{"issue":"1","key":"957_CR155","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/s41467-025-60798-y","volume":"16","author":"Y Shen","year":"2025","unstructured":"Shen Y, Wang H, Guo D, Liu J, Sun J, Chen N, et al. Dual asparagine-depriving nanoparticles against solid tumors. Nat Commun. 2025;16(1):5675. https:\/\/doi.org\/10.1038\/s41467-025-60798-y.","journal-title":"Nat Commun"},{"issue":"5","key":"957_CR156","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s42255-025-01245-6","volume":"7","author":"HC Chang","year":"2025","unstructured":"Chang HC, Tsai CY, Hsu CL, Tai TS, Cheng ML, Chuang YM, et al. Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations. Nat Metab. 2025;7(5):918\u201327. https:\/\/doi.org\/10.1038\/s42255-025-01245-6.","journal-title":"Nat Metab"},{"key":"957_CR157","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of Erastin in ferroptosis and its prospects in cancer therapy. OTT. 2020, 13: 5429\u201341. https:\/\/doi.org\/10.2147\/OTT.S254995.","journal-title":"OTT"},{"issue":"12","key":"957_CR158","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0338.","journal-title":"Cancer Discov"},{"issue":"34","key":"957_CR159","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.1074\/jbc.M117.798405","volume":"292","author":"P Koppula","year":"2017","unstructured":"Koppula P, Zhang Y, Shi J, Li W, Gan B. The glutamate\/cystine antiporter SLC7A11\/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017;292(34):14240\u201349. https:\/\/doi.org\/10.1074\/jbc.M117.798405.","journal-title":"J Biol Chem"},{"issue":"2","key":"957_CR160","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523\u201330. https:\/\/doi.org\/10.1007\/s00280-012-2045-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"957_CR161","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"M Stein","year":"2010","unstructured":"Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. The Prostate. 2010;70(13):1388\u201394. https:\/\/doi.org\/10.1002\/pros.21172.","journal-title":"The Prostate"},{"issue":"7","key":"957_CR162","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-06-3717","volume":"67","author":"AL Simons","year":"2007","unstructured":"Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67(7):3364\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3717.","journal-title":"Cancer Res"},{"issue":"18","key":"957_CR163","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-20-0113","volume":"26","author":"S Wang","year":"2020","unstructured":"Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res. 2020;26(18):4921\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0113.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"957_CR164","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","volume":"16","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zhang C, Najafi M. Targeting of the tumor immune microenvironment by metformin. J Cell Commun Signal. 2022;16(3):333\u201348. https:\/\/doi.org\/10.1007\/s12079-021-00648-w.","journal-title":"J Cell Commun Signal"},{"issue":"6","key":"957_CR165","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1073\/pnas.1417636112","volume":"112","author":"S Eikawa","year":"2015","unstructured":"Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112(6):1809\u201314. https:\/\/doi.org\/10.1073\/pnas.1417636112.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"957_CR166","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1016\/j.celrep.2018.11.043","volume":"25","author":"D Benjamin","year":"2018","unstructured":"Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, et al. Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep. 2018;25(11):3047\u201358.e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.043.","journal-title":"Cell Rep"},{"key":"957_CR167","doi-asserted-by":"publisher","unstructured":"Babl N, Decking SM, Voll F, Althammer M, Sala-Hojman A, Ferretti R, et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. J Immunother Cancer. 2023;11(10):e007349. https:\/\/doi.org\/10.1136\/jitc-2023-007349.","DOI":"10.1136\/jitc-2023-007349"},{"key":"957_CR168","doi-asserted-by":"publisher","first-page":"114605","DOI":"10.1016\/j.ejmech.2022.114605","volume":"240","author":"L Di Magno","year":"2022","unstructured":"Di Magno L, Coluccia A, Bufano M, Ripa S, La Regina G, Nalli M, et al. Discovery of novel human lactate dehydrogenase inhibitors: structure-based virtual screening studies and biological assessment. Eur J Med Chem. 2022;240:114605. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114605.","journal-title":"Eur J Med Chem"},{"issue":"19","key":"957_CR169","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-19-0217","volume":"79","author":"C Yeung","year":"2019","unstructured":"Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, et al. Targeting glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing Sarcoma. Cancer Res. 2019;79(19):5060\u201373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0217.","journal-title":"Cancer Res"},{"issue":"5","key":"957_CR170","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ijc.28114","volume":"133","author":"T Ohashi","year":"2013","unstructured":"Ohashi T, Akazawa T, Aoki M, Kuze B, Mizuta K, Ito Y, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Intl J Cancer. 2013;133(5):1107\u201318. https:\/\/doi.org\/10.1002\/ijc.28114.","journal-title":"Intl J Cancer"},{"issue":"3","key":"957_CR171","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10637-015-0221-y","volume":"33","author":"QS-C Chu","year":"2015","unstructured":"Chu QS-C, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJB, et al. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. Invest New Drugs. 2015;33(3):603\u201310. https:\/\/doi.org\/10.1007\/s10637-015-0221-y.","journal-title":"Invest New Drugs"},{"issue":"3","key":"957_CR172","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10637-013-0047-4","volume":"32","author":"EM Dunbar","year":"2014","unstructured":"Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs. 2014;32(3):452\u201364. https:\/\/doi.org\/10.1007\/s10637-013-0047-4.","journal-title":"Invest New Drugs"},{"issue":"7","key":"957_CR173","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bjc.6604554","volume":"99","author":"ED Michelakis","year":"2008","unstructured":"Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989\u201394. https:\/\/doi.org\/10.1038\/sj.bjc.6604554.","journal-title":"Br J Cancer"},{"key":"957_CR174","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100797.","journal-title":"EClinicalMedicine"},{"issue":"37","key":"957_CR175","doi-asserted-by":"publisher","first-page":"24787","DOI":"10.18632\/oncotarget.25361","volume":"9","author":"YY Zaytseva","year":"2018","unstructured":"Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, et al. Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 2018;9(37):24787\u2013800. https:\/\/doi.org\/10.18632\/oncotarget.25361.","journal-title":"Oncotarget"},{"issue":"11","key":"957_CR176","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res. 2015;3(11):1236\u201347. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0036.","journal-title":"Cancer Immunol Res"},{"key":"957_CR177","doi-asserted-by":"publisher","unstructured":"Liu Z, Liu W, Wang W, Ma Y, Wang Y, Drum DL, et al. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc Natl Acad Sci USA. 2023;120(39):e2302878120. https:\/\/doi.org\/10.1073\/pnas.2302878120.","DOI":"10.1073\/pnas.2302878120"},{"key":"957_CR178","doi-asserted-by":"publisher","unstructured":"Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019;11(478). https:\/\/doi.org\/10.1126\/scitranslmed.aau5758.","DOI":"10.1126\/scitranslmed.aau5758"},{"issue":"17","key":"957_CR179","doi-asserted-by":"publisher","first-page":"9438","DOI":"10.3390\/ijms25179438","volume":"25","author":"M Takaichi","year":"2024","unstructured":"Takaichi M, Tachinami H, Takatsuka D, Yonesi A, Sakurai K, Rasul MI, et al. Targeting CD36-mediated lipid metabolism by selective inhibitor-augmented antitumor immune responses in Oral cancer. IJMS. 2024;25(17):9438. https:\/\/doi.org\/10.3390\/ijms25179438.","journal-title":"IJMS"},{"issue":"7","key":"957_CR180","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00432-022-03957-8","volume":"148","author":"C Ruan","year":"2022","unstructured":"Ruan C, Meng Y, Song H. CD36: an emerging therapeutic target for cancer and its molecular mechanisms. J Cancer ResearchClin Oncol. 2022;148(7):1551\u201358. https:\/\/doi.org\/10.1007\/s00432-022-03957-8.","journal-title":"J Cancer ResearchClin Oncol"},{"issue":"1","key":"957_CR181","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41467-021-22967-7","volume":"12","author":"NM Schmidt","year":"2021","unstructured":"Schmidt NM, Wing PAC, Diniz MO, Pallett LJ, Swadling L, Harris JM, et al. Targeting human acyl-CoA: cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. Nat Commun. 2021;12(1):2814. https:\/\/doi.org\/10.1038\/s41467-021-22967-7.","journal-title":"Nat Commun"},{"key":"957_CR182","doi-asserted-by":"publisher","first-page":"1395192","DOI":"10.3389\/fonc.2024.1395192","volume":"14","author":"T Sun","year":"2024","unstructured":"Sun T, Xiao X. Targeting ACAT1 in cancer: from threat to treatment. Front Oncol. 2024;14:1395192. https:\/\/doi.org\/10.3389\/fonc.2024.1395192.","journal-title":"Front Oncol"},{"key":"957_CR183","doi-asserted-by":"publisher","unstructured":"O\u2019Keefe S, Wang Q. ACAT1 regulates tertiary lymphoid structures: a target for enhancing immunotherapy in non\u2013small cell lung cancer. J Clin Investigation. 2025;135(7). https:\/\/doi.org\/10.1172\/JCI191094.","DOI":"10.1172\/JCI191094"},{"key":"957_CR184","doi-asserted-by":"publisher","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","volume":"13","author":"K Jin","year":"2023","unstructured":"Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells. Front Oncol. 2023;13:1099811. https:\/\/doi.org\/10.3389\/fonc.2023.1099811.","journal-title":"Front Oncol"},{"key":"957_CR185","doi-asserted-by":"publisher","first-page":"637504","DOI":"10.3389\/fonc.2021.637504","volume":"11","author":"D Pu","year":"2021","unstructured":"Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, et al. Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer. Front Oncol. 2021;11:637504. https:\/\/doi.org\/10.3389\/fonc.2021.637504.","journal-title":"Front Oncol"},{"issue":"7","key":"957_CR186","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72(7):2443\u201358. https:\/\/doi.org\/10.1007\/s00262-023-03430-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"957_CR187","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, et al. Phase Ia\/b, Open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin Cancer Res. 2022;28(22):4871\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0612.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"957_CR188","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10637-018-0706-6","volume":"37","author":"L Seitz","year":"2019","unstructured":"Seitz L, Jin L, Leleti M, Ashok D, Jeffrey J, Rieger A, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019;37(4):711\u201321. https:\/\/doi.org\/10.1007\/s10637-018-0706-6.","journal-title":"Invest New Drugs"},{"issue":"6","key":"957_CR189","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/0006-2952(95)00255-X","volume":"50","author":"S Greene","year":"1995","unstructured":"Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacol. 1995;50(6):861\u201367. https:\/\/doi.org\/10.1016\/0006-2952(95)00255-X.","journal-title":"Biochemical Pharmacol"},{"issue":"2","key":"957_CR190","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1158\/1535-7163.MCT-05-0340","volume":"5","author":"N Takebe","year":"2006","unstructured":"Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006;5(2):457\u201366. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0340.","journal-title":"Mol Cancer Ther"},{"key":"957_CR191","doi-asserted-by":"crossref","unstructured":"Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, et al. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. bioRxiv. 2024.","DOI":"10.7554\/eLife.87292.2"},{"issue":"18","key":"957_CR192","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1158\/1078-0432.CCR-14-0624","volume":"20","author":"I Gehrke","year":"2014","unstructured":"Gehrke I, Bouchard EDJ, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin Cancer Res. 2014;20(18):4861\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0624.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"957_CR193","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbrc.2015.01.111","volume":"458","author":"S Schuster","year":"2015","unstructured":"Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W, et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem Bioph Res Co. 2015;458(2):334\u201340. https:\/\/doi.org\/10.1016\/j.bbrc.2015.01.111.","journal-title":"Biochem Bioph Res Co"},{"issue":"9","key":"957_CR194","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov. 2018;8(9):1156\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1033.","journal-title":"Cancer Discov"},{"issue":"7","key":"957_CR195","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24(7):1036\u201346. https:\/\/doi.org\/10.1038\/s41591-018-0052-4.","journal-title":"Nat Med"},{"issue":"1","key":"957_CR196","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29(1):115\u201326. https:\/\/doi.org\/10.1038\/s41591-022-02103-8.","journal-title":"Nat Med"},{"issue":"11","key":"957_CR197","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1111\/cas.14615","volume":"111","author":"A Saito","year":"2020","unstructured":"Saito A, Kitayama J, Horie H, Koinuma K, Ohzawa H, Yamaguchi H, et al. Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. Cancer Sci. 2020;111(11):4012\u201320. https:\/\/doi.org\/10.1111\/cas.14615.","journal-title":"Cancer Sci"},{"issue":"5","key":"957_CR198","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell"},{"issue":"11","key":"957_CR199","first-page":"6417","volume":"34","author":"E Lachaier","year":"2014","unstructured":"Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34(11):6417\u201322.","journal-title":"Anticancer Res"},{"key":"957_CR200","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","volume":"9","author":"X Sui","year":"2018","unstructured":"Sui X, Zhang R, Liu S, Duan T, Zhai L, Zhang M, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9:1371. https:\/\/doi.org\/10.3389\/fphar.2018.01371.","journal-title":"Front Pharmacol"},{"issue":"12","key":"957_CR201","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1084\/jem.20182044","volume":"216","author":"S Di Biase","year":"2019","unstructured":"Di Biase S, Ma X, Wang X, Yu J, Wang YC, Smith DJ, et al. Creatine uptake regulates CD8 T cell antitumor immunity. J Exp Med. 2019;216(12):2869\u201382. https:\/\/doi.org\/10.1084\/jem.20182044.","journal-title":"J Exp Med"},{"key":"957_CR202","doi-asserted-by":"publisher","first-page":"1176956","DOI":"10.3389\/fimmu.2023.1176956","volume":"14","author":"Z Peng","year":"2023","unstructured":"Peng Z, Saito S. Creatine supplementation enhances anti-tumor immunity by promoting adenosine triphosphate production in macrophages. Front Immunol. 2023;14:1176956. https:\/\/doi.org\/10.3389\/fimmu.2023.1176956.","journal-title":"Front Immunol"},{"issue":"9","key":"957_CR203","doi-asserted-by":"publisher","first-page":"110446","DOI":"10.1016\/j.celrep.2022.110446","volume":"38","author":"B Samborska","year":"2022","unstructured":"Samborska B, Roy DG, Rahbani JF, Hussain MF, Ma EH, Jones RG, et al. Creatine transport and creatine kinase activity is required for CD8+ T cell immunity. Cell Rep. 2022;38(9):110446. https:\/\/doi.org\/10.1016\/j.celrep.2022.110446.","journal-title":"Cell Rep"},{"issue":"7","key":"957_CR204","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 2020;43(7):484\u201390. https:\/\/doi.org\/10.1097\/COC.0000000000000691.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"957_CR205","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","volume":"7","author":"SC Chafe","year":"2019","unstructured":"Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and Systemically. Cancer Immunol Res. 2019;7(7):1064\u201378. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0657.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"957_CR206","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","volume":"34","author":"E Andreucci","year":"2019","unstructured":"Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzym Inhib Med Chem. 2019;34(1):117\u201323. https:\/\/doi.org\/10.1080\/14756366.2018.1532419.","journal-title":"J Enzym Inhib Med Chem"},{"issue":"11","key":"957_CR207","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.3390\/cancers12113292","volume":"12","author":"M Palviainen","year":"2020","unstructured":"Palviainen M, Laukkanen K, Tavukcuoglu Z, Velagapudi V, K\u00e4rkk\u00e4inen O, Hanhineva K, et al. Cancer alters the metabolic fingerprint of extracellular vesicles. Cancers (Basel). 2020;12(11):3292. https:\/\/doi.org\/10.3390\/cancers12113292.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"957_CR208","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.mcpro.2025.100944","volume":"24","author":"YJ Lee","year":"2025","unstructured":"Lee YJ, Seo CW, Chae S, Lee CY, Kim SS, Shin YH, et al. Metabolic reprogramming into a glycolysis phenotype induced by extracellular vesicles derived from prostate cancer cells. Mol Cellular Proteomics. 2025;24(4):100944. https:\/\/doi.org\/10.1016\/j.mcpro.2025.100944.","journal-title":"Mol Cellular Proteomics"},{"issue":"2\u20133","key":"957_CR209","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/pmic.70081","volume":"26","author":"L Yu","year":"2026","unstructured":"Yu L, Ding T, Olofsson Bagge R, Zheng L, Hao X. Proteomics of prostate cancer tissue small extracellular vesicles reveal alteration of metabolism. Proteomics. 2026;26(2\u20133):121\u201328. https:\/\/doi.org\/10.1002\/pmic.70081.","journal-title":"Proteomics"},{"issue":"1","key":"957_CR210","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41392-022-00960-w","volume":"7","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen D, Song D, Liu X, Zhang Y, Xu X, et al. Clinical and translational values of spatial transcriptomics. Sig Transduct Target Ther. 2022;7(1):111. https:\/\/doi.org\/10.1038\/s41392-022-00960-w.","journal-title":"Sig Transduct Target Ther"},{"issue":"11","key":"957_CR211","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/s41416-024-02882-6","volume":"131","author":"T Semba","year":"2024","unstructured":"Semba T, Ishimoto T. Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues. Br J Cancer. 2024;131(11):1737\u201347. https:\/\/doi.org\/10.1038\/s41416-024-02882-6.","journal-title":"Br J Cancer"},{"issue":"6294","key":"957_CR212","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aaf2403","volume":"353","author":"PL St\u00e5hl","year":"2016","unstructured":"St\u00e5hl PL, Salm\u00e9n F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78\u201382. https:\/\/doi.org\/10.1126\/science.aaf2403.","journal-title":"Science"},{"issue":"9","key":"957_CR213","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347. https:\/\/doi.org\/10.1038\/s41588-021-00911-1.","journal-title":"Nat Genet"},{"issue":"4","key":"957_CR214","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.2869","volume":"11","author":"C Giesen","year":"2014","unstructured":"Giesen C, Wang HAO, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417\u201322. https:\/\/doi.org\/10.1038\/nmeth.2869.","journal-title":"Nat Methods"},{"issue":"5","key":"957_CR215","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586\u201399. https:\/\/doi.org\/10.1038\/s41587-020-0472-9.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"957_CR216","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","volume":"8","author":"HL Williams","year":"2024","unstructured":"Williams HL, Frei AL, Koessler T, Berger MD, Dawson H, Michielin O, et al. The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. NPJ Precis Onc. 2024;8(1):178. https:\/\/doi.org\/10.1038\/s41698-024-00671-1.","journal-title":"NPJ Precis Onc"},{"key":"957_CR217","doi-asserted-by":"publisher","unstructured":"Pu Y, Zhou Y, Guo T, Pan X, Sun X, Yang G, et al. MIF promotes phenotypic switching of VSMCs via AKT\/mTOR-mediated autophagy regulation in aortic dissection. Faseb J. 2025;39(19):e71079. https:\/\/doi.org\/10.1096\/fj.202501761R.","DOI":"10.1096\/fj.202501761R"},{"key":"957_CR218","doi-asserted-by":"publisher","unstructured":"Naghinezhad J, Zarifi N, Soleymani S, Kandovan MN, Chermehini NY, Hamblin MR, et al. Smart DNA hydrogels for post-surgical hemostasis and tumor recurrence prevention: bridging bioengineering and clinical translation. Cancer Nanotechnol. 2026;17(1). https:\/\/doi.org\/10.1186\/s12645-025-00355-w.","DOI":"10.1186\/s12645-025-00355-w"},{"key":"957_CR219","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, et al. Tumor cell-targeting and tumor microenvironment\u2013responsive nanoplatforms for the multimodal imaging-guided Photodynamic\/Photothermal\/Chemodynamic treatment of cervical cancer. IJN. 2024;19:5837\u201358. https:\/\/doi.org\/10.2147\/IJN.S466042.","journal-title":"IJN"},{"issue":"4","key":"957_CR220","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-018-9896-8","volume":"35","author":"M Alieva","year":"2018","unstructured":"Alieva M, van Rheenen J, Broekman MLD. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis. 2018;35(4):319\u201331. https:\/\/doi.org\/10.1007\/s10585-018-9896-8.","journal-title":"Clin Exp Metastasis"},{"key":"957_CR221","doi-asserted-by":"publisher","unstructured":"Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci USA. 2013;110(5):E415\u201324. https:\/\/doi.org\/10.1073\/pnas.1211850110.","DOI":"10.1073\/pnas.1211850110"},{"key":"957_CR222","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jss.2022.11.064","volume":"283","author":"Y Jiao","year":"2023","unstructured":"Jiao Y, Lv Q. Does primary tumor resection induce Accelerated metastasis in breast cancer? A review. J Retailing Surg Res. 2023;283:1005\u201317. https:\/\/doi.org\/10.1016\/j.jss.2022.11.064.","journal-title":"J Retailing Surg Res"},{"issue":"1","key":"957_CR223","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1186\/s12885-025-15087-8","volume":"25","author":"Q Feng","year":"2025","unstructured":"Feng Q, Ni C, Zhou F, Zhu J, Sun X, Qin Y, et al. Clinical relevance of perioperative changes in circulating tumor cells in resectable colorectal cancer. BMC Cancer. 2025;25(1):1689. https:\/\/doi.org\/10.1186\/s12885-025-15087-8.","journal-title":"BMC Cancer"},{"issue":"7","key":"957_CR224","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","volume":"77","author":"S Tohme","year":"2017","unstructured":"Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1536.","journal-title":"Cancer Res"},{"key":"957_CR225","doi-asserted-by":"publisher","first-page":"888630","DOI":"10.3389\/fsurg.2022.888630","volume":"9","author":"H Choi","year":"2022","unstructured":"Choi H, Hwang W. Perioperative inflammatory response and cancer recurrence in lung cancer surgery: a narrative review. Front. Surg. 2022;9:888630. https:\/\/doi.org\/10.3389\/fsurg.2022.888630.","journal-title":"Front. Surg"},{"issue":"12","key":"957_CR226","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.3390\/jcm9124096","volume":"9","author":"AE Onuma","year":"2020","unstructured":"Onuma AE, Zhang H, Gil L, Huang H, Tsung A. Surgical stress promotes tumor progression: a focus on the impact of the immune response. JCM. 2020;9(12):4096. https:\/\/doi.org\/10.3390\/jcm9124096.","journal-title":"JCM"},{"issue":"1","key":"957_CR227","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021;6(1):263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"957_CR228","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1172\/JCI67484","volume":"123","author":"J Cools-Lartigue","year":"2013","unstructured":"Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446\u201358. https:\/\/doi.org\/10.1172\/JCI67484.","journal-title":"J. Clin. Invest"},{"key":"957_CR229","doi-asserted-by":"publisher","unstructured":"Liao K, Zhang X, Liu J, Teng F, He Y, Cheng J, et al. The\u2009role of platelets in\u2009the regulation\u2009of tumor growth\u2009and metastasis: the\u2009mechanisms and targeted therapy. MedComm (2020). 2023;4(5):e350. https:\/\/doi.org\/10.1002\/mco2.350.","DOI":"10.1002\/mco2.350"},{"issue":"6","key":"957_CR230","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965\u201383. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.002.","journal-title":"Cancer Cell"},{"issue":"6","key":"957_CR231","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09537104.2018.1453059","volume":"29","author":"AK Olsson","year":"2018","unstructured":"Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets. 2018;29(6):569\u201373. https:\/\/doi.org\/10.1080\/09537104.2018.1453059.","journal-title":"Platelets"},{"issue":"1","key":"957_CR232","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ctm2.24","volume":"10","author":"F Tang","year":"2020","unstructured":"Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199\u2013223. https:\/\/doi.org\/10.1002\/ctm2.24.","journal-title":"Clin Transl Med"},{"issue":"1","key":"957_CR233","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12967-018-1389-7","volume":"16","author":"R Kim","year":"2018","unstructured":"Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018;16(1):8. https:\/\/doi.org\/10.1186\/s12967-018-1389-7.","journal-title":"J Transl Med"},{"issue":"5","key":"957_CR234","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/bja\/aet068","volume":"110","author":"JP Cata","year":"2013","unstructured":"Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110(5):690\u2013701. https:\/\/doi.org\/10.1093\/bja\/aet068.","journal-title":"Br J Anaesth"},{"key":"957_CR235","doi-asserted-by":"publisher","unstructured":"Yao YL, Xu Z, Xiao R, Li EH, Zhang YJ, Zhou LY, et al. Elevated neutrophil, lymphocyte, and platelet counts as early biomarkers of preeclampsia risk: a retrospective cohort study. Am J Rep Immunol. 2025;94(2):e70137. https:\/\/doi.org\/10.1111\/aji.70137.","DOI":"10.1111\/aji.70137"},{"issue":"6","key":"957_CR236","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/wrr.13170","volume":"32","author":"EC Townsend","year":"2024","unstructured":"Townsend EC, Cheong JZA, Radzietza M, Fritz B, Malone M, Bjarnsholt T, et al. What is slough? Defining the proteomic and microbial composition of slough and its implications for wound healing. Wound Repair Regener. 2024;32(6):783\u201398. https:\/\/doi.org\/10.1111\/wrr.13170.","journal-title":"Wound Repair Regener"},{"issue":"9","key":"957_CR237","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.bjc.6604004","volume":"97","author":"BL Murthy","year":"2007","unstructured":"Murthy BL, Thomson CS, Dodwell D, Shenoy H, Mikeljevic JS, Forman D, et al. Postoperative wound complications and systemic recurrence in breast cancer. Br J Cancer. 2007;97(9):1211\u201317. https:\/\/doi.org\/10.1038\/sj.bjc.6604004.","journal-title":"Br J Cancer"},{"issue":"2","key":"957_CR238","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/jcm10020228","volume":"10","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita T, Goto T. Links between inflammation and postoperative cancer recurrence. JCM. 2021;10(2):228. https:\/\/doi.org\/10.3390\/jcm10020228.","journal-title":"JCM"},{"key":"957_CR239","doi-asserted-by":"publisher","first-page":"217413","DOI":"10.1016\/j.canlet.2024.217413","volume":"611","author":"F Zeng","year":"2025","unstructured":"Zeng F, Shao Y, Wu J, Luo J, Yue Y, Shen Y, et al. Tumor metastasis and recurrence: the role of perioperative NETosis. Cancer Lett. 2025;611:217413. https:\/\/doi.org\/10.1016\/j.canlet.2024.217413.","journal-title":"Cancer Lett"},{"issue":"3","key":"957_CR240","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12029-013-9491-9","volume":"44","author":"S Wan","year":"2013","unstructured":"Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44(3):293\u2013304. https:\/\/doi.org\/10.1007\/s12029-013-9491-9.","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"957_CR241","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","volume":"9","author":"X Shi","year":"2024","unstructured":"Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Sig Transduct Target Ther. 2024;9(1):192. https:\/\/doi.org\/10.1038\/s41392-024-01885-2.","journal-title":"Sig Transduct Target Ther"},{"issue":"21","key":"957_CR242","doi-asserted-by":"publisher","first-page":"11378","DOI":"10.3390\/ijms222111378","volume":"22","author":"M Market","year":"2021","unstructured":"Market M, Tennakoon G, Auer RC. Postoperative natural killer cell dysfunction: the prime suspect in the case of metastasis following curative cancer surgery. IJMS. 2021;22(21):11378. https:\/\/doi.org\/10.3390\/ijms222111378.","journal-title":"IJMS"},{"key":"957_CR243","doi-asserted-by":"publisher","unstructured":"Acharya K, Rout DK, Kapadia NA, Caroicar YS, Karunakaran NB, Patel P, et al. Surgical stress response: a physiological review of the endocrine, immune, and metabolic changes. Cureus. 2025;17(12):e100101. https:\/\/doi.org\/10.7759\/cureus.100101.","DOI":"10.7759\/cureus.100101"},{"issue":"5","key":"957_CR244","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/cen.13820","volume":"89","author":"A Prete","year":"2018","unstructured":"Prete A, Yan Q, Al-Tarrah K, Akturk HK, Prokop LJ, Alahdab F, et al. The cortisol stress response induced by surgery: a systematic review and meta-analysis. Clin Endocrinol (Oxford). 2018;89(5):554\u201367. https:\/\/doi.org\/10.1111\/cen.13820.","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"1","key":"957_CR245","doi-asserted-by":"publisher","first-page":"2284486","DOI":"10.1080\/2162402X.2023.2284486","volume":"12","author":"K Carnet Le Provost","year":"2023","unstructured":"Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. Trial watch: beta-blockers in cancer therapy. Oncoimmunology. 2023;12(1):2284486. https:\/\/doi.org\/10.1080\/2162402X.2023.2284486.","journal-title":"Oncoimmunology"},{"issue":"9","key":"957_CR246","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/jth.14891","volume":"18","author":"M Marchetti","year":"2020","unstructured":"Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, et al. Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemostasis. 2020;18(9):2220\u201331. https:\/\/doi.org\/10.1111\/jth.14891.","journal-title":"J Thromb Haemostasis"},{"key":"957_CR247","doi-asserted-by":"publisher","first-page":"783218","DOI":"10.3389\/fsurg.2021.783218","volume":"8","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhao Y, Quan Y, Ma X. Targeting myeloid-derived suppressor cells derived from surgical stress: the key to prevent post-surgical metastasis. Front. Surg. 2021;8:783218. https:\/\/doi.org\/10.3389\/fsurg.2021.783218.","journal-title":"Front. Surg"},{"issue":"6","key":"957_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mco.2025.2848","volume":"22","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Li W, Chen Y, Hu X, Miao C. Research progress on the impact of opioids on the tumor immune microenvironment (review). Mol Clin Oncol. 2025;22(6):1\u201311. https:\/\/doi.org\/10.3892\/mco.2025.2848.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"957_CR249","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12288-018-0962-9","volume":"34","author":"K Abdolmohammadi","year":"2018","unstructured":"Abdolmohammadi K, Mahmoudi T, Jafari-Koshki T, Hassan ZM, Pourfathollah AA. Immunomodulatory effects of blood transfusion on tumor size, metastasis, and survival in experimental fibrosarcoma. Indian J Hematol Blood Transfus. 2018;34(4):697\u2013702. https:\/\/doi.org\/10.1007\/s12288-018-0962-9.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"957_CR250","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.transci.2017.05.019","volume":"56","author":"H Goubran","year":"2017","unstructured":"Goubran H, Sheridan D, Radosevic J, Burnouf T, Seghatchian J. Transfusion-related immunomodulation and cancer. Tranfus Apheresis Sci. 2017;56(3):336\u201340. https:\/\/doi.org\/10.1016\/j.transci.2017.05.019.","journal-title":"Tranfus Apheresis Sci"},{"issue":"11","key":"957_CR251","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1097\/JS9.0000000000002021","volume":"110","author":"E Sandbank","year":"2024","unstructured":"Sandbank E, Matzner P, Eckerling A, Sorski L, Rossene E, Nachmani I, et al. Perioperative hypothermia and stress jeopardize antimetastatic immunity and TLR-9 immune activation: potential mediating mechanisms (experimental studies). Int J Surg. 2024;110(11):6941\u201352. https:\/\/doi.org\/10.1097\/JS9.0000000000002021.","journal-title":"Int J Surg"},{"issue":"7","key":"957_CR252","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.7150\/thno.69795","volume":"12","author":"J Li","year":"2022","unstructured":"Li J, Li J, Yao Y, Yong T, Bie N, Wei Z, et al. Biodegradable electrospun nanofibrous platform integrating antiplatelet therapy-chemotherapy for preventing postoperative tumor recurrence and metastasis. Theranostics. 2022;12(7):3503\u201317. https:\/\/doi.org\/10.7150\/thno.69795.","journal-title":"Theranostics"},{"issue":"1","key":"957_CR253","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12935-024-03481-4","volume":"24","author":"Z Lin","year":"2024","unstructured":"Lin Z, Hua G, Hu X. Lipid metabolism associated crosstalk: the bidirectional interaction between cancer cells and immune\/stromal cells within the tumor microenvironment for prognostic insight. Cancer Cell Int. 2024;24(1):295. https:\/\/doi.org\/10.1186\/s12935-024-03481-4.","journal-title":"Cancer Cell Int"},{"issue":"24","key":"957_CR254","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/0008-5472.CAN-24-3393","volume":"85","author":"T Haykal","year":"2025","unstructured":"Haykal T, Yang R, Tohme C, He Z, Liu S, Geller DA, et al. Surgery-induced neutrophil extracellular traps promote tumor metastasis by reprogramming cancer cell lipid metabolism. Cancer Res. 2025;85(24):4995\u20135014. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-3393.","journal-title":"Cancer Res"},{"issue":"13","key":"957_CR255","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3390\/cancers16132304","volume":"16","author":"L Bezu","year":"2024","unstructured":"Bezu L, Ak\u00e7al \u00d6ks\u00fcz D, Bell M, Buggy D, Diaz-Cambronero O, Enlund M, et al. Perioperative immunosuppressive factors during cancer surgery: an updated review. Cancers (Basel). 2024;16(13):2304. https:\/\/doi.org\/10.3390\/cancers16132304.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"957_CR256","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86. https:\/\/doi.org\/10.1186\/s40425-018-0398-7.","journal-title":"J Immunother Cancer"},{"key":"957_CR257","doi-asserted-by":"publisher","first-page":"204062072311527","DOI":"10.1177\/20406207231152746","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang L, Xu J, Zhang H, Wang M, Zhang Y, Lin Q. Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia. Ther Adv Hematol. 2023;14:20406207231152746. https:\/\/doi.org\/10.1177\/20406207231152746.","journal-title":"Ther Adv Hematol"},{"key":"957_CR258","doi-asserted-by":"crossref","unstructured":"Boudreaux MK, Christopherson PW. Thrombopoiesis. In: Schalm\u2019s veterinary hematology. 2022. p. 649\u201357.","DOI":"10.1002\/9781119500537.ch75"},{"key":"957_CR259","doi-asserted-by":"crossref","unstructured":"Gremmel T, Frelinger Iii AL, Michelson AD, editors. Platelet physiology. Seminars in thrombosis and hemostasis. Thieme Medical Publishers; 2016.","DOI":"10.1055\/s-0035-1564835"},{"issue":"1","key":"957_CR260","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MOH.0000000000000792","volume":"31","author":"O An","year":"2024","unstructured":"An O, Deppermann C. Platelet lifespan and mechanisms for clearance. Curr Opin Hematol. 2024;31(1):6\u201315. https:\/\/doi.org\/10.1097\/MOH.0000000000000792.","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"957_CR261","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/mi12101175","volume":"12","author":"M Sugihara-Seki","year":"2021","unstructured":"Sugihara-Seki M, Takinouchi N. Margination of platelet-sized particles in the red blood cell suspension flow through square Microchannels. Micromachines (Basel). 2021;12(10):1175. https:\/\/doi.org\/10.3390\/mi12101175.","journal-title":"Micromachines (Basel)"},{"key":"957_CR262","doi-asserted-by":"publisher","first-page":"985905","DOI":"10.3389\/fphys.2022.985905","volume":"13","author":"C Kotsalos","year":"2022","unstructured":"Kotsalos C, Raynaud F, L\u00e4tt J, Dutta R, Dubois F, Zouaoui Boudjeltia K, et al. Shear induced diffusion of platelets revisited. Front Physiol. 2022;13:985905. https:\/\/doi.org\/10.3389\/fphys.2022.985905.","journal-title":"Front. Physiol"},{"issue":"1","key":"957_CR263","doi-asserted-by":"publisher","first-page":"37350","DOI":"10.1038\/s41598-025-22429-w","volume":"15","author":"A Elhanafy","year":"2025","unstructured":"Elhanafy A, Elsagheer S, Nada S. Numerical simulation of red blood cells migration and platelets margination for blood flow in micro-vessels with fusiform aneurysms. Sci Rep. 2025;15(1):37350. https:\/\/doi.org\/10.1038\/s41598-025-22429-w.","journal-title":"Sci Rep"},{"issue":"8","key":"957_CR264","doi-asserted-by":"publisher","first-page":"083603","DOI":"10.1103\/PhysRevFluids.9.083603","volume":"9","author":"M Dynar","year":"2024","unstructured":"Dynar M, Ez-Zahraouy H, Misbah C, Abbasi M. Platelet margination dynamics in blood flow: the role of lift forces and red blood cells aggregation. Phys Rev Fluids. 2024;9(8):083603. https:\/\/doi.org\/10.1103\/PhysRevFluids.9.083603.","journal-title":"Phys Rev Fluids"},{"issue":"12","key":"957_CR265","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1161\/ATVBAHA.110.207522","volume":"30","author":"Z Li","year":"2010","unstructured":"Li Z, Delaney MK, O\u2019Brien KA, Du X. Signaling during platelet adhesion and activation. ATVB. 2010;30(12):2341\u201349. https:\/\/doi.org\/10.1161\/ATVBAHA.110.207522.","journal-title":"ATVB"},{"issue":"4","key":"957_CR266","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3324\/haematol.2020.278242","volume":"107","author":"A Constantinescu-Bercu","year":"2022","unstructured":"Constantinescu-Bercu A, Wang YA, Woollard KJ, Mangin P, Vanhoorelbeke K, Crawley JTB, et al. The GPIb\u03b1 intracellular tail - role in transducing VWF- and collagen\/GPVI-mediated signaling. Haematologica. 2022;107(4):933\u201346.","journal-title":"Haematologica"},{"issue":"2","key":"957_CR267","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2006-11-058107","volume":"110","author":"T Rabie","year":"2007","unstructured":"Rabie T, Varga-Szabo D, Bender M, Pozgaj R, Lanza F, Saito T, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood. 2007;110(2):529\u201335. https:\/\/doi.org\/10.1182\/blood-2006-11-058107.","journal-title":"Blood"},{"key":"957_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/erm.2026.10047","volume":"28","author":"J Naghinezhad","year":"2026","unstructured":"Naghinezhad J, Mohajerian A, Ahadi S, Khodakarim N, Hamblin M, Rezaeeyan H. When GPVI Goes rogue: pathogenesis and therapeutic horizons in ITP. Expert Rev Mol Med. 2026;28:1\u201341. https:\/\/doi.org\/10.1017\/erm.2026.10047.","journal-title":"Expert Rev. Mol. Med"},{"issue":"12","key":"957_CR269","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/jth.13147","volume":"13","author":"H Heijnen","year":"2015","unstructured":"Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules \u2026 or not? J Thromb Haemostasis. 2015;13(12):2141\u201351. https:\/\/doi.org\/10.1111\/jth.13147.","journal-title":"J Thromb Haemostasis"},{"issue":"21","key":"957_CR270","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.3390\/ijms232112772","volume":"23","author":"A Scridon","year":"2022","unstructured":"Scridon A. Platelets and their role in hemostasis and thrombosis\u2014from physiology to pathophysiology and therapeutic implications. IJMS. 2022;23(21):12772. https:\/\/doi.org\/10.3390\/ijms232112772.","journal-title":"IJMS"},{"issue":"11","key":"957_CR271","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1016\/j.jtha.2025.08.004","volume":"23","author":"HE Allan","year":"2025","unstructured":"Allan HE, Dark N, Vulliamy P, Crescente M, Maffucci T, Armstrong PC, et al. Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function. J Thromb Haemostasis. 2025;23(11):3665\u201377. https:\/\/doi.org\/10.1016\/j.jtha.2025.08.004.","journal-title":"J Thromb Haemostasis"},{"key":"957_CR272","doi-asserted-by":"publisher","first-page":"678362","DOI":"10.3389\/fphys.2021.678362","volume":"12","author":"M Mussbacher","year":"2021","unstructured":"Mussbacher M, Pirabe A, Brunnthaler L, Schrottmaier WC, Assinger A. Horizontal MicroRNA transfer by platelets \u2013 evidence and implications. Front Physiol. 2021;12:678362. https:\/\/doi.org\/10.3389\/fphys.2021.678362.","journal-title":"Front. Physiol"},{"issue":"9","key":"957_CR273","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1158\/0008-5472.CAN-20-3222","volume":"81","author":"J Ren","year":"2021","unstructured":"Ren J, He J, Zhang H, Xia Y, Hu Z, Loughran P, et al. Platelet TLR4-ERK5 axis facilitates NET-Mediated capturing of circulating tumor cells and distant metastasis after surgical stress. Cancer Res. 2021;81(9):2373\u201385. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3222.","journal-title":"Cancer Res"},{"issue":"1","key":"957_CR274","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-021-01347-1","volume":"20","author":"MP Ward","year":"2021","unstructured":"Ward MP, Ek L, An L, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; Friend or foe of the circulating tumour cell? Mol Cancer. 2021;20(1):59. https:\/\/doi.org\/10.1186\/s12943-021-01347-1.","journal-title":"Mol Cancer"},{"key":"957_CR275","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fonc.2020.01350","volume":"10","author":"S Lucotti","year":"2020","unstructured":"Lucotti S, Muschel RJ. Platelets\u2009and metastasis:\u2009new implications of an old\u2009interplay.\u2009Front Oncol. 2020;10:1350. https:\/\/doi.org\/10.3389\/fonc.2020.01350.","journal-title":"Front Oncol"},{"issue":"5","key":"957_CR276","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009.","journal-title":"Cancer Cell"},{"issue":"4","key":"957_CR277","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.7150\/jca.103757","volume":"16","author":"C Zhong","year":"2025","unstructured":"Zhong C, Wang W, Yao Y, Lian S, Xie X, Xu J, et al. TGF-\u03b2 secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation. J Cancer. 2025;16(4):1310\u201323. https:\/\/doi.org\/10.7150\/jca.103757.","journal-title":"J Cancer"},{"issue":"1","key":"957_CR278","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12645-025-00340-3","volume":"16","author":"J Naghinezhad","year":"2025","unstructured":"Naghinezhad J, Moradpanah S, Khodakarim N, Hamblin MR, Rezaeeyan H. Nanodrug-based modulation of platelet\u2013leukocyte interactions in ovarian cancer: a new frontier in targeted therapy. Cancer Nanotechnol. 2025;16(1):37. https:\/\/doi.org\/10.1186\/s12645-025-00340-3.","journal-title":"Cancer Nanotechnol"},{"issue":"1","key":"957_CR279","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s40001-023-01342-w","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L, Zhang Z, Tian Y, Li Z, Liu Z, Zhu S. The critical role of platelet in cancer progression and metastasis. Eur J Med Res. 2023;28(1):385. https:\/\/doi.org\/10.1186\/s40001-023-01342-w.","journal-title":"Eur J Med Res"},{"key":"957_CR280","doi-asserted-by":"publisher","first-page":"0948","DOI":"10.34133\/research.0948","volume":"8","author":"B Huang","year":"2025","unstructured":"Huang B, An H, Wu H, Qiu Y, Su Y, Chen L, et al. Chronic psychological stress in oncogenesis: multisystem crosstalk and multimodal interventions. Res (Wash D C). 2025;8:0948. https:\/\/doi.org\/10.34133\/research.0948.","journal-title":"Res (Wash D C)"},{"key":"957_CR281","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.jtauto.2025.100309","volume":"11","author":"F Farhid","year":"2025","unstructured":"Farhid F, Rezaeeyan H, Habibi R, Kamali Yazdi E, Hamblin MR, Naghinezhad J. When the victim becomes the villain: platelets as drivers of immune dysregulation in ITP. J Transl Autoimmun. 2025;11:100309. https:\/\/doi.org\/10.1016\/j.jtauto.2025.100309.","journal-title":"J. Transl. Autoimmun"},{"key":"957_CR282","doi-asserted-by":"publisher","unstructured":"Heydari F, Chermehini NY, Safari Z, Hamblin MR, Naghinezhad J. Targeting glycoprotein VI (GPVI) in cancer: mechanistic insights and therapeutic strategies to suppress metastasis and thrombosis. Cancer Nanotechnol. 2026. https:\/\/doi.org\/10.1186\/s12645-026-00375-0.","DOI":"10.1186\/s12645-026-00375-0"},{"key":"957_CR283","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/erm.2026.10043","volume":"28","author":"J Naghinezhad","year":"2026","unstructured":"Naghinezhad J, Yazdi E, Mohajerian A, Chermehini N, Ghanavati P, Motamedi H, et al. The tumor\u2013platelet\u2013immune Interface: driving metastasis, pre-metastatic niche formation and therapeutic vulnerabilities. Expert Rev Mol Med. 2026;28:1\u201334. https:\/\/doi.org\/10.1017\/erm.2026.10043.","journal-title":"Expert Rev. Mol. Med"},{"issue":"15","key":"957_CR284","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1111\/bph.70032","volume":"182","author":"L Lin","year":"2025","unstructured":"Lin L, Sun B, Hu Y, Yang W, Li J, Wang D, et al. Rhynchophylline as an agonist of sirtuin 3 ameliorates endothelial dysfunction via antagonizing mitochondrial damage of endothelial progenitor cells. Br J Pharmacol. 2025;182(15):3476\u2013502. https:\/\/doi.org\/10.1111\/bph.70032.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"957_CR285","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2013.06.009","volume":"24","author":"BZ Stanger","year":"2013","unstructured":"Stanger BZ, Kahn ML. Platelets and tumor cells: a new form of border control. Cancer Cell. 2013;24(1):9\u201311. https:\/\/doi.org\/10.1016\/j.ccr.2013.06.009.","journal-title":"Cancer Cell"},{"issue":"15","key":"957_CR286","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.3390\/ijms26157150","volume":"26","author":"DV Scripcariu","year":"2025","unstructured":"Scripcariu DV, Huzum B, Mircea C, Tesoi DF, Badulescu OV. Systemic impact of platelet activation in abdominal surgery: from oxidative and inflammatory pathways to postoperative complications. IJMS. 2025;26(15):7150. https:\/\/doi.org\/10.3390\/ijms26157150.","journal-title":"IJMS"},{"issue":"2","key":"957_CR287","doi-asserted-by":"publisher","first-page":"407","DOI":"10.62347\/JAYK5667","volume":"15","author":"J Yang","year":"2025","unstructured":"Yang J, Xu P, Zhang G, Wang D, Ye B, Wu L. Advances and potentials in platelet-circulating tumor cell crosstalk. Am J Cancer Res. 2025;15(2):407\u201325.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"957_CR288","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s44161-022-00021-z","volume":"1","author":"T Tyagi","year":"2022","unstructured":"Tyagi T, Jain K, Gu SX, Qiu M, Gu VW, Melchinger H, et al. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nat Cardiovasc Res. 2022;1(3):223\u201337. https:\/\/doi.org\/10.1038\/s44161-022-00021-z.","journal-title":"Nat Cardiovasc Res"},{"issue":"3","key":"957_CR289","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/j.2040-4603.2015.tb00649.x","volume":"5","author":"FW Lam","year":"2015","unstructured":"Lam FW, Vijayan KV, Rumbaut RE. Platelets and their interactions with other immune cells. Compr Physiol. 2015;5(3):1265\u201380. https:\/\/doi.org\/10.1002\/j.2040-4603.2015.tb00649.x.","journal-title":"Compr Physiol"},{"key":"957_CR290","doi-asserted-by":"publisher","unstructured":"Wang S, Duan Y, Zhang Q, Komarla A, Gong H, Gao W, et al. Drug targeting via platelet membrane\u2013coated nanoparticles. Small Struct. 2020;1(1). https:\/\/doi.org\/10.1002\/sstr.202000018.","DOI":"10.1002\/sstr.202000018"},{"issue":"17","key":"957_CR291","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1039\/D3BM00893B","volume":"11","author":"C Yao","year":"2023","unstructured":"Yao C, Wang C. Platelet-derived extracellular vesicles for drug delivery. Biomater Sci. 2023;11(17):5758\u201368. https:\/\/doi.org\/10.1039\/D3BM00893B.","journal-title":"Biomater Sci"},{"issue":"7","key":"957_CR292","doi-asserted-by":"publisher","first-page":"828","DOI":"10.7150\/ijbs.19776","volume":"13","author":"SC Tao","year":"2017","unstructured":"Tao SC, Guo SC, Zhang CQ. Platelet-derived extracellular vesicles: an emerging therapeutic approach. Int J Biol Sci. 2017;13(7):828\u201334. https:\/\/doi.org\/10.7150\/ijbs.19776.","journal-title":"Int. J. Biol. Sci"},{"key":"957_CR293","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.2147\/IJN.S333279","volume":"16","author":"L Wu","year":"2021","unstructured":"Wu L, Li Q, Deng J, Shen J, Xu W, Yang W, et al. Platelet-tumor cell hybrid membrane-Camouflaged nanoparticles for enhancing therapy efficacy in glioma. IJN. 2021;16:8433\u201346. https:\/\/doi.org\/10.2147\/IJN.S333279.","journal-title":"IJN"},{"key":"957_CR294","doi-asserted-by":"publisher","first-page":"983874","DOI":"10.3389\/fonc.2022.983874","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Hu L, Tan C, Wang X, Ran Q, Chen L, et al. Platelet-promoting drug delivery efficiency for inhibition of tumor growth, metastasis, and recurrence. Front Oncol. 2022;12:983874. https:\/\/doi.org\/10.3389\/fonc.2022.983874.","journal-title":"Front Oncol"},{"key":"957_CR295","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fbioe.2020.00133","volume":"8","author":"MW Kim","year":"2020","unstructured":"Kim MW, Lee G, Niidome T, Komohara Y, Lee R, Park YI. Platelet-like Gold nanostars for cancer therapy: the ability to treat cancer and evade immune Reactions. Front Bioeng Biotechnol. 2020;8:133. https:\/\/doi.org\/10.3389\/fbioe.2020.00133.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"957_CR296","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40364-024-00639-0","volume":"12","author":"T Zhuang","year":"2024","unstructured":"Zhuang T, Wang S, Yu X, He X, Guo H, Ou C. Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment. Biomark Res. 2024;12(1):88. https:\/\/doi.org\/10.1186\/s40364-024-00639-0.","journal-title":"Biomark Res"},{"key":"957_CR297","doi-asserted-by":"publisher","unstructured":"Wang Y, Li W, Li Z, Mo F, Chen Y, Iida M, et al. Active recruitment of anti\u2013PD-1\u2013conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. Sci Adv. 2023;9(13):eadf 6854. https:\/\/doi.org\/10.1126\/sciadv.adf6854.","DOI":"10.1126\/sciadv.adf6854"},{"issue":"9","key":"957_CR298","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","volume":"18","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang J, Chen Z, Hu Q, Wang C, Yan J, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018;18(9):5716\u201325. https:\/\/doi.org\/10.1021\/acs.nanolett.8b02321.","journal-title":"Nano Lett"},{"key":"957_CR299","doi-asserted-by":"publisher","unstructured":"Wang Y, Ogunnaike E, Yang H, Yuan S, Hong R, Barrett A, et al. Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery. Proc Natl Acad Sci USA. 2025;122(51):e2522020122. https:\/\/doi.org\/10.1073\/pnas.2522020122.","DOI":"10.1073\/pnas.2522020122"},{"issue":"4","key":"957_CR300","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/anie.201709457","volume":"57","author":"L Rao","year":"2018","unstructured":"Rao L, Bu LL, Ma L, Wang W, Liu H, Wan D, et al. Platelet-facilitated photothermal therapy of head and neck squamous cell carcinoma. Angew Chem Int Ed Engl. 2018;57(4):986\u201391. https:\/\/doi.org\/10.1002\/anie.201709457.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"957_CR301","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-025-00676-x","volume":"14","author":"C Cai","year":"2025","unstructured":"Cai C, Liu Y, Lu R, Fan X, Zeng S, Gan P. Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities. Exp Hematol Oncol. 2025;14(1):83. https:\/\/doi.org\/10.1186\/s40164-025-00676-x.","journal-title":"Exp Hematol Oncol"},{"key":"957_CR302","doi-asserted-by":"publisher","first-page":"101683","DOI":"10.1016\/j.mtbio.2025.101683","volume":"32","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang Z, Wang J, Lin Y, Gao H, Wang P, et al. Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer. Mater Today Bio. 2025;32:101683. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101683.","journal-title":"Mater Today Bio"},{"issue":"8","key":"957_CR303","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biomedicines12081850","volume":"12","author":"B Muttiah","year":"2024","unstructured":"Muttiah B, Ng SL, Lokanathan Y, Ng MH, Law JX. Beyond blood clotting: the many Roles of platelet-derived extracellular vesicles. Biomedicines. 2024;12(8):1850. https:\/\/doi.org\/10.3390\/biomedicines12081850.","journal-title":"Biomedicines"},{"key":"957_CR304","doi-asserted-by":"publisher","first-page":"879351","DOI":"10.3389\/fcvm.2022.879351","volume":"9","author":"Q Leng","year":"2022","unstructured":"Leng Q, Ding J, Dai M, Liu L, Fang Q, Wang DW, et al. Insights into platelet-derived MicroRNAs in Cardiovascular and oncologic diseases: potential predictor and therapeutic target. Front Cardiovasc Med. 2022;9:879351. https:\/\/doi.org\/10.3389\/fcvm.2022.879351.","journal-title":"Front. Cardiovasc. Med"},{"issue":"23","key":"957_CR305","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/blood.2019003977","volume":"137","author":"DL Tao","year":"2021","unstructured":"Tao DL, Tassi Yunga S, Williams CD, McCarty OJT. Aspirin and antiplatelet treatments in cancer. Blood. 2021;137(23):3201\u201311. https:\/\/doi.org\/10.1182\/blood.2019003977.","journal-title":"Blood"},{"issue":"7","key":"957_CR306","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjmed.2017.01.022","volume":"130","author":"A Leader","year":"2017","unstructured":"Leader A, Zelikson-Saporta R, Pereg D, Spectre G, Rozovski U, Raanani P, et al. The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med. 2017;130(7):826\u201332. https:\/\/doi.org\/10.1016\/j.amjmed.2017.01.022.","journal-title":"Am J Med"},{"key":"957_CR307","doi-asserted-by":"publisher","unstructured":"Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med. 2016;8(345):345ra87. https:\/\/doi.org\/10.1126\/scitranslmed.aaf7374.","DOI":"10.1126\/scitranslmed.aaf7374"},{"issue":"1","key":"957_CR308","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-018-0659-4","volume":"11","author":"Y Qi","year":"2018","unstructured":"Qi Y, Chen W, Liang X, Xu K, Gu X, Wu F, et al. Novel antibodies against GPIb\u03b1 inhibit pulmonary metastasis by affecting vWF-GPIb\u03b1 interaction. J Hematol Oncol. 2018;11(1):117. https:\/\/doi.org\/10.1186\/s13045-018-0659-4.","journal-title":"J Hematol Oncol"},{"key":"957_CR309","doi-asserted-by":"publisher","unstructured":"Zuchtriegel G, Uhl B, Puhr-Westerheide D, P\u00f6rnbacher M, Lauber K, Krombach F, et al. Platelets guide leukocytes to their sites of extravasation. PLoS Biol. 2016;14(5):e1002459. https:\/\/doi.org\/10.1371\/journal.pbio.1002459.","DOI":"10.1371\/journal.pbio.1002459"},{"key":"957_CR310","doi-asserted-by":"publisher","first-page":"123205","DOI":"10.1016\/j.biomaterials.2025.123205","volume":"319","author":"GS Liu","year":"2025","unstructured":"Liu GS, Chen HA, Chang CY, Chen YJ, Wu YY, Widhibrata A, et al. Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization. Biomaterials. 2025;319:123205. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123205.","journal-title":"Biomaterials"},{"key":"957_CR311","doi-asserted-by":"publisher","first-page":"117131","DOI":"10.1016\/j.biopha.2024.117131","volume":"177","author":"M Fang","year":"2024","unstructured":"Fang M, Liu R, Fang Y, Zhang D, Kong B. Emerging platelet-based drug delivery systems. Biomed Pharmacother. 2024;177:117131. https:\/\/doi.org\/10.1016\/j.biopha.2024.117131.","journal-title":"Biomed Pharmacother"},{"key":"957_CR312","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3389\/fphar.2019.01256","volume":"10","author":"F Taus","year":"2019","unstructured":"Taus F, Meneguzzi A, Castelli M, Minuz P. Platelet-derived extracellular vesicles as target of antiplatelet agents. What is the evidence? Front Pharmacol. 2019;10:1256. https:\/\/doi.org\/10.3389\/fphar.2019.01256.","journal-title":"Front Pharmacol"},{"issue":"2","key":"957_CR313","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"957_CR314","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jtha.2024.12.016","volume":"23","author":"EC Josefsson","year":"2025","unstructured":"Josefsson EC. Platelets and megakaryocytes in cancer. J Thromb Haemostasis. 2025;23(3):804\u201316. https:\/\/doi.org\/10.1016\/j.jtha.2024.12.016.","journal-title":"J Thromb Haemostasis"},{"key":"957_CR315","doi-asserted-by":"publisher","first-page":"103502","DOI":"10.1016\/j.critrevonc.2021.103502","volume":"167","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhang Y, Ding Y, Zhuang R. Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules. Crit Rev Oncol\/Hematol. 2021;167:103502. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103502.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"957_CR316","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-024-05126-6","volume":"22","author":"J Xue","year":"2024","unstructured":"Xue J, Deng J, Qin H, Yan S, Zhao Z, Qin L, et al. The interaction of platelet-related factors with tumor cells promotes tumor metastasis. J Transl Med. 2024;22(1):371. https:\/\/doi.org\/10.1186\/s12967-024-05126-6.","journal-title":"J Transl Med"},{"key":"957_CR317","doi-asserted-by":"publisher","first-page":"1165989","DOI":"10.3389\/fimmu.2023.1165989","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Wang H, Zhao Z, Yang Y, Meng Z, Qin L. Effects of the interactions between platelets with other cells in tumor growth and progression. Front Immunol. 2023;14:1165989. https:\/\/doi.org\/10.3389\/fimmu.2023.1165989.","journal-title":"Front Immunol"},{"issue":"21","key":"957_CR318","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1039\/D0TB00735H","volume":"8","author":"L Wu","year":"2020","unstructured":"Wu L, Xie W, Zan HM, Liu Z, Wang G, Wang Y, et al. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. J Mater Chem B. 2020;8(21):4648\u201359. https:\/\/doi.org\/10.1039\/D0TB00735H.","journal-title":"J Mater Chem B"},{"issue":"9","key":"957_CR319","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1039\/D0NA00271B","volume":"2","author":"N Ortiz-Otero","year":"2020","unstructured":"Ortiz-Otero N, Marshall JR, Lash BW, King MR. Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells. Nanoscale Adv. 2020;2(9):3942\u201353. https:\/\/doi.org\/10.1039\/D0NA00271B.","journal-title":"Nanoscale Adv"},{"key":"957_CR320","doi-asserted-by":"publisher","first-page":"14149","DOI":"10.2147\/IJN.S558928","volume":"20","author":"B Liu","year":"2025","unstructured":"Liu B, Wang Y, Gong W, Han S, Lv Z, Zhang Z, et al. Natural, engineered, and hybrid platelet membrane\u2013based nanotherapeutics for inflammatory diseases. IJN. 2025;20:14149\u201384. https:\/\/doi.org\/10.2147\/IJN.S558928.","journal-title":"IJN"},{"issue":"5","key":"957_CR321","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10147-004-0429-x","volume":"9","author":"M Sasako","year":"2004","unstructured":"Sasako M. Role of surgery in multidisciplinary treatment for solid cancers. Int J Clin Oncol. 2004;9(5):346\u201351. https:\/\/doi.org\/10.1007\/s10147-004-0429-x.","journal-title":"Int J Clin Oncol"},{"issue":"1152","key":"957_CR322","doi-asserted-by":"publisher","first-page":"20230334","DOI":"10.1259\/bjr.20230334","volume":"96","author":"T Mee","year":"2023","unstructured":"Mee T, Kirkby NF, Defourny NN, Kirkby KJ, Burnet NG. The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (favourable outcomes from RadioTherapY) project. The Br J Radiol. 2023;96(1152):20230334. https:\/\/doi.org\/10.1259\/bjr.20230334.","journal-title":"The Br J Radiol"},{"key":"957_CR323","doi-asserted-by":"crossref","unstructured":"Sabel MS, Diehl KM, Chang AE. Principles of surgical therapy in oncology. In: Oncology: an evidence-based approach. Springer; 2006. p. 58\u201372.","DOI":"10.1007\/0-387-31056-8_4"},{"issue":"1","key":"957_CR324","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clinicians. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clinicians"},{"key":"957_CR325","doi-asserted-by":"publisher","unstructured":"He W, Li Z, Xie Q, Han Y, Peng L, Wang C, et al. Long-term survival outcomes of NCRT with surgery vs surgery with adjuvant therapy for ESCC: a single-center prospective phase 3 randomized clinical trial. JAMA Netw Open. 2026;9(1):e2550307\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.50307.","DOI":"10.1001\/jamanetworkopen.2025.50307"},{"issue":"1","key":"957_CR326","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/nrclinonc.2015.212","volume":"13","author":"CM Balch","year":"2016","unstructured":"Balch CM, Nelson H, Niederhuber JE. Limitations of prospective surgical oncology trials \u2014 a US view. Nat Rev Clin Oncol. 2016;13(1):6\u20138. https:\/\/doi.org\/10.1038\/nrclinonc.2015.212.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"957_CR327","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3350\/cmh.2020.0016","volume":"26","author":"J Kim","year":"2020","unstructured":"Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol. 2020;26(4):516\u201328. https:\/\/doi.org\/10.3350\/cmh.2020.0016.","journal-title":"Clin Mol Hepatol"},{"key":"957_CR328","doi-asserted-by":"publisher","first-page":"103107","DOI":"10.1016\/j.ebiom.2020.103107","volume":"62","author":"KQ Zhou","year":"2020","unstructured":"Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, et al. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine. 2020;62:103107. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103107.","journal-title":"EBioMedicine"},{"issue":"1","key":"957_CR329","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-026-01740-3","volume":"28","author":"KYK Cheung","year":"2026","unstructured":"Cheung KYK, Parks RM, Giza D, Cheung K-L. Surgery in older cancer patients. Curr Oncol Rep. 2026;28(1):1. https:\/\/doi.org\/10.1007\/s11912-026-01740-3.","journal-title":"Curr Oncol Rep"},{"key":"957_CR330","unstructured":"Bobin JY, Delay E, Rivoire M. [Role of surgery in the treatment of cancer. Surgical oncology]. Bull Cancer. 1995;82 Suppl 2( Suppl, 2):113s\u201326."},{"issue":"4","key":"957_CR331","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/gidisord5040046","volume":"5","author":"A Ruivo","year":"2023","unstructured":"Ruivo A, Oliveira RC, Silva-Vaz P, Tralh\u00e3o JG. Colorectal cancer Liver metastasis\u2014state-of-the-art and future perspectives. Gastrointestinal Disord. 2023;5(4):580\u2013608. https:\/\/doi.org\/10.3390\/gidisord5040046.","journal-title":"Gastrointestinal Disord"},{"issue":"4","key":"957_CR332","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clinicians. 2025;75(4):308\u201340. https:\/\/doi.org\/10.3322\/caac.70011.","journal-title":"CA Cancer J Clinicians"},{"issue":"3","key":"957_CR333","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12012-026-10104-z","volume":"26","author":"F Heydari","year":"2026","unstructured":"Heydari F, Feli M, Maleknia M, Habibi Z, Sohrabi A, Hamblin MR, et al. Beyond remission: the cardiotoxic and thrombotic shadow of AML chemotherapy. Cardiovasc Toxicol. 2026;26(3):31. https:\/\/doi.org\/10.1007\/s12012-026-10104-z.","journal-title":"Cardiovasc Toxicol"},{"key":"957_CR334","doi-asserted-by":"publisher","unstructured":"Chen EY, Rai M, Tadikonda Y, Roy P, Nollner DW, Chitkara A, et al. Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US food and drug administration. Oncologist. 2025;30(3):oyae302. https:\/\/doi.org\/10.1093\/oncolo\/oyae302.","DOI":"10.1093\/oncolo\/oyae302"},{"issue":"5","key":"957_CR335","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10637-024-01472-w","volume":"42","author":"L Peng","year":"2024","unstructured":"Peng L, Wu Z, Sun W, Wang C. Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia. Invest New Drugs. 2024;42(5):575\u201380. https:\/\/doi.org\/10.1007\/s10637-024-01472-w.","journal-title":"Invest New Drugs"},{"issue":"1","key":"957_CR336","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","volume":"16","author":"A Zafar","year":"2025","unstructured":"Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025;16(1):607. https:\/\/doi.org\/10.1007\/s12672-025-02198-8.","journal-title":"Discov Oncol"},{"key":"957_CR337","doi-asserted-by":"publisher","first-page":"1614325","DOI":"10.3389\/fphar.2025.1614325","volume":"16","author":"ZM Althafar","year":"2025","unstructured":"Althafar ZM. Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions. Front Pharmacol. 2025;16:1614325. https:\/\/doi.org\/10.3389\/fphar.2025.1614325.","journal-title":"Front Pharmacol"},{"issue":"10475","key":"957_CR338","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","volume":"405","author":"II Verginadis","year":"2025","unstructured":"Verginadis II, Citrin DE, Ky B, Feigenberg SJ, Georgakilas AG, Hill-Kayser CE, et al. Radiotherapy toxicities: mechanisms, management, and future directions. Lancet. 2025;405(10475):338\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)02319-5.","journal-title":"Lancet"},{"issue":"1","key":"957_CR339","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1186\/s12885-025-14328-0","volume":"25","author":"M Tan","year":"2025","unstructured":"Tan M, Li L, Tan B, Yang J. Innovations in modern low-LET radiotherapy regimens for locally advanced non-small cell lung cancer: a meta-analysis and systematic review of high-dose-rate brachytherapy, stereotactic body radiotherapy, and hypofractionated proton therapy. BMC Cancer. 2025;25(1):942. https:\/\/doi.org\/10.1186\/s12885-025-14328-0.","journal-title":"BMC Cancer"},{"key":"957_CR340","doi-asserted-by":"publisher","unstructured":"Reddy S, Upadhyay R, Klamer B, Singh R, Konieczkowski D, Cripe T, et al. Local control and toxicity outcomes after stereotactic body radiation therapy for metastatic osteosarcoma in pediatric patients. Pediatr Blood Cancer. 2025;72(9):e31834. https:\/\/doi.org\/10.1002\/pbc.31834.","DOI":"10.1002\/pbc.31834"},{"issue":"8","key":"957_CR341","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.21037\/jtd-2025-423","volume":"17","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang P, Zhao D, Yang T, Sun M, Li Y, et al. Efficacy and safety of postoperative adjuvant immunotherapy for esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2025;17(8):5575\u201387. https:\/\/doi.org\/10.21037\/jtd-2025-423.","journal-title":"J Thorac Dis"},{"issue":"3","key":"957_CR342","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.esmoop.2025.104295","volume":"10","author":"M Donia","year":"2025","unstructured":"Donia M, Jespersen H, Jalving M, Lee R, Eriksson H, Hoeller C, et al. Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open. 2025;10(3):104295. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104295.","journal-title":"ESMO Open"},{"key":"957_CR343","doi-asserted-by":"publisher","unstructured":"Huang H, Li L, Tong L, Luo H, Luo H, Zhang Q. Perioperative PD-1\/PD-L1 inhibitors for resectable non-small cell lung cancer: a meta-analysis based on randomized controlled trials. PLoS ONE. 2024;19(9):e0310808. https:\/\/doi.org\/10.1371\/journal.pone.0310808.","DOI":"10.1371\/journal.pone.0310808"},{"issue":"1","key":"957_CR344","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1744666X.2016.1214575","volume":"13","author":"KE Beckermann","year":"2017","unstructured":"Beckermann KE, Johnson DB, Sosman JA. PD-1\/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. 2017;13(1):77\u201384. https:\/\/doi.org\/10.1080\/1744666X.2016.1214575.","journal-title":"Expert Rev Clin Immunol"},{"key":"957_CR345","doi-asserted-by":"publisher","first-page":"1569864","DOI":"10.3389\/fimmu.2025.1569864","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Lin Y, Chen S. Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis. Front Immunol. 2025;16:1569864. https:\/\/doi.org\/10.3389\/fimmu.2025.1569864.","journal-title":"Front Immunol"},{"key":"957_CR346","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1051\/vcm\/2025004","volume":"6","author":"J Ji","year":"2025","unstructured":"Ji J, Liu Y, Bao Y, Men Y, Wang J, Hui Z. Review of radiotherapy combined with systemic therapy for advanced esophageal cancer: from chemotherapy to immunotherapy era. Vis Cancer Med. 2025;6:5. https:\/\/doi.org\/10.1051\/vcm\/2025004.","journal-title":"Vis Cancer Med"},{"issue":"9","key":"957_CR347","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.21037\/tlcr-2025-426","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang L, Zhao X, Sun D, Zhou H, Zhang Y, et al. Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis. Transl Lung Cancer Res. 2025;14(9):3378\u201395. https:\/\/doi.org\/10.21037\/tlcr-2025-426.","journal-title":"Transl Lung Cancer Res"},{"issue":"Pt 3","key":"957_CR348","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","volume":"86","author":"X Cheng","year":"2022","unstructured":"Cheng X, Zhang H, Hamad A, Huang H, Tsung A. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 2022;86(Pt 3):408\u201319. https:\/\/doi.org\/10.1016\/j.semcancer.2022.01.006.","journal-title":"Semin Cancer Biol"},{"key":"957_CR349","doi-asserted-by":"publisher","first-page":"1172108","DOI":"10.3389\/fgene.2023.1172108","volume":"14","author":"L Zhu","year":"2023","unstructured":"Zhu L, Xu R, Yang L, Shi W, Zhang Y, Liu J, et al. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review. Front Genet. 2023;14:1172108. https:\/\/doi.org\/10.3389\/fgene.2023.1172108.","journal-title":"Front Genet"},{"issue":"16","key":"957_CR350","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-25-0307","volume":"31","author":"ES Sim","year":"2025","unstructured":"Sim ES, Rhoades J, Xiong K, Walsh L, Crnjac A, Blewett T, et al. Early postoperative minimal residual disease detection with MAESTRO is associated with recurrence and worse survival in patients with head and neck cancer. Clin Cancer Res. 2025;31(16):3494\u2013502. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0307.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"957_CR351","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/cancers16132316","volume":"16","author":"KY Tsai","year":"2024","unstructured":"Tsai KY, Huang PS, Chu PY, Nguyen TNA, Hung HY, Hsieh CH, et al. Current applications and future directions of circulating tumor cells in colorectal cancer recurrence. Cancers (Basel). 2024;16(13):2316. https:\/\/doi.org\/10.3390\/cancers16132316.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"957_CR352","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s11605-013-2258-6","volume":"17","author":"G Galizia","year":"2013","unstructured":"Galizia G, Gemei M, Orditura M, Romano C, Zamboli A, Castellano P, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointestinal Surg. 2013;17(10):1809\u201318. https:\/\/doi.org\/10.1007\/s11605-013-2258-6.","journal-title":"J Gastrointestinal Surg"},{"issue":"6","key":"957_CR353","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s12276-022-00784-2","volume":"54","author":"SB Kwak","year":"2022","unstructured":"Kwak SB, Kim SJ, Kim J, Kang YL, Ko CW, Kim I, et al. Tumor regionalization after surgery: roles of the tumor microenvironment and neutrophil extracellular traps. Exp Mol Med. 2022;54(6):720\u201329. https:\/\/doi.org\/10.1038\/s12276-022-00784-2.","journal-title":"Exp Mol Med"},{"issue":"24","key":"957_CR354","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.3390\/cancers16244269","volume":"16","author":"H Choi","year":"2024","unstructured":"Choi H, Hwang W. Anesthetic approaches and their impact on cancer recurrence and metastasis: a comprehensive review. Cancers (Basel). 2024;16(24):4269. https:\/\/doi.org\/10.3390\/cancers16244269.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"957_CR355","doi-asserted-by":"publisher","first-page":"20230117","DOI":"10.1002\/VIW.20230117","volume":"5","author":"M Xiao","year":"2024","unstructured":"Xiao M, Wang L, Tang Q, Yang Q, Yang X, Zhu G, et al. Postoperative tumor treatment strategies: from basic research to clinical therapy. View. 2024;5(3):20230117. https:\/\/doi.org\/10.1002\/VIW.20230117.","journal-title":"View"},{"key":"957_CR356","doi-asserted-by":"publisher","first-page":"105109","DOI":"10.1016\/j.ebiom.2024.105109","volume":"103","author":"J Zheng","year":"2024","unstructured":"Zheng J, Qin C, Wang Q, Tian D, Chen Z. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis. EBioMedicine. 2024;103:105109. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105109.","journal-title":"EBioMedicine"},{"key":"957_CR357","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.acr.2018.12.002","volume":"141","author":"S Talukdar","year":"2019","unstructured":"Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43\u201384.","journal-title":"Adv Cancer Res"},{"issue":"7","key":"957_CR358","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807\u201317. https:\/\/doi.org\/10.1038\/ncb2767.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"957_CR359","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2025.9007","volume":"55","author":"L Zhang","year":"2025","unstructured":"Zhang L, Yuan Y, Deng Y, Wang L, Chen F. Platelet\u2011circulating tumor cell crosstalk: a pivotal target in cancer diagnosis and therapy (Review). Oncol Rep. 2025;55(1):1\u201314. https:\/\/doi.org\/10.3892\/or.2025.9007.","journal-title":"Oncol Rep"},{"issue":"11","key":"957_CR360","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"key":"957_CR361","doi-asserted-by":"publisher","first-page":"1545000","DOI":"10.3389\/fimmu.2025.1545000","volume":"16","author":"K Silihe Kamga","year":"2025","unstructured":"Silihe Kamga K, Fiering S. Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach. Front Immunol. 2025;16:1545000. https:\/\/doi.org\/10.3389\/fimmu.2025.1545000.","journal-title":"Front Immunol"},{"key":"957_CR362","doi-asserted-by":"publisher","first-page":"101308","DOI":"10.1016\/j.mtbio.2024.101308","volume":"29","author":"Z Zhong","year":"2024","unstructured":"Zhong Z, Gan L, Feng Z, Wang W, Pan X, Wu C, et al. Hydrogel local drug delivery systems for postsurgical management of tumors: status quo and perspectives. Mater Today Bio. 2024;29:101308. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101308.","journal-title":"Mater Today Bio"},{"key":"957_CR363","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.mtbio.2023.100839","volume":"23","author":"C Huang","year":"2023","unstructured":"Huang C, Shao N, Huang Y, Chen J, Wang D, Hu G, et al. Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: a comprehensive review of strategies and future perspectives. Mater Today Bio. 2023;23:100839. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100839.","journal-title":"Mater Today Bio"},{"issue":"24","key":"957_CR364","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3390\/cancers14246091","volume":"14","author":"S Bhatnagar","year":"2022","unstructured":"Bhatnagar S, Revuri V, Shah M, Larson P, Shao Z, Yu D, et al. Combination of STING and TLR 7\/8 agonists as vaccine adjuvants for cancer immunotherapy. Cancers (Basel). 2022;14(24):6091. https:\/\/doi.org\/10.3390\/cancers14246091.","journal-title":"Cancers (Basel)"},{"key":"957_CR365","doi-asserted-by":"publisher","unstructured":"Park CG, Hartl CA, Schmid D, Carmona EM, Kim H-J, Goldberg MS. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018;10(433):eaar1916. https:\/\/doi.org\/10.1126\/scitranslmed.aar1916.","DOI":"10.1126\/scitranslmed.aar1916"},{"issue":"8","key":"957_CR366","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1039\/D3BM00003F","volume":"11","author":"Q Qian","year":"2023","unstructured":"Qian Q, Song J, Chen C, Pu Q, Liu X, Wang H. Recent advances in hydrogels for preventing tumor recurrence. Biomater Sci. 2023;11(8):2678\u201392. https:\/\/doi.org\/10.1039\/D3BM00003F.","journal-title":"Biomater Sci"},{"issue":"10","key":"957_CR367","doi-asserted-by":"publisher","first-page":"102399","DOI":"10.1016\/j.xcrm.2025.102399","volume":"6","author":"C Guo","year":"2025","unstructured":"Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R, et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med. 2025;6(10):102399. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102399.","journal-title":"Cell Rep. Med"},{"issue":"8","key":"957_CR368","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28(8):1630\u201339. https:\/\/doi.org\/10.1038\/s41591-022-01897-x.","journal-title":"Nat Med"},{"key":"957_CR369","doi-asserted-by":"publisher","first-page":"1308890","DOI":"10.3389\/fimmu.2023.1308890","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2023;14:1308890. https:\/\/doi.org\/10.3389\/fimmu.2023.1308890.","journal-title":"Front Immunol"},{"issue":"19","key":"957_CR370","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. JNCI J Natl Cancer Inst. 2007;99(19):1441\u201354. https:\/\/doi.org\/10.1093\/jnci\/djm135.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"957_CR371","doi-asserted-by":"publisher","unstructured":"Wang S, Yang C, Chen L. LSA-DDI: learning stereochemistry-aware drug interactions via 3D Feature fusion and contrastive cross-attention. IJMS. 2025;26(14):6799 p. https:\/\/doi.org\/10.3390\/ijms26146799.","DOI":"10.3390\/ijms26146799"},{"issue":"1","key":"957_CR372","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","volume":"7","author":"M Bayat","year":"2026","unstructured":"Bayat M, Nahand JS. CAR-engineered cell therapies: current understandings and future perspectives. Mol Biomed. 2026;7(1):7. https:\/\/doi.org\/10.1186\/s43556-025-00401-4.","journal-title":"Mol Biomed"},{"key":"957_CR373","doi-asserted-by":"publisher","unstructured":"First-ever CAR T-cell therapy approved in US. Cancer Discov. 2017;7(10):OF1\u20131. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-126.","DOI":"10.1158\/2159-8290.CD-NB2017-126"},{"issue":"4","key":"957_CR374","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2035.","journal-title":"Clin Cancer Res"},{"key":"957_CR375","volume-title":"Restoring chimeric antigen receptor (CAR) T cell function in chronic lymphocytic leukaemia","author":"R Sanderson","year":"2020","unstructured":"Sanderson R. Restoring chimeric antigen receptor (CAR) T cell function in chronic lymphocytic leukaemia. CLL: Queen Mary University of London; 2020."},{"issue":"26","key":"957_CR376","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"2","key":"957_CR377","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2301665.","journal-title":"N Engl J Med"},{"issue":"6","key":"957_CR378","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"957_CR379","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"issue":"4","key":"957_CR380","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"21","key":"957_CR381","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","volume":"9","author":"X Desch\u00eanes-Simard","year":"2025","unstructured":"Desch\u00eanes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, et al. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025;9(21):5571\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2025016778.","journal-title":"Blood Adv"},{"key":"957_CR382","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, et al. Axicabtagene ciloleucel versus Tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplant Cellular Ther. 2024;30(6):.e584.1\u2013.13. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.074.","DOI":"10.1016\/j.jtct.2024.01.074"},{"issue":"20","key":"957_CR383","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood. 2023;141(20):2430\u201342. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"key":"957_CR384","doi-asserted-by":"publisher","first-page":"1659251","DOI":"10.3389\/fimmu.2025.1659251","volume":"16","author":"W Ma","year":"2025","unstructured":"Ma W, Gu Z, Lin Q, Cao M, Zhong J, Li X, et al. Integrative genetic and multi-omics analysis reveals the interleukin-6 receptor\u2019s role in recurrent spontaneous abortion. Front Immunol. 2025;16:1659251. https:\/\/doi.org\/10.3389\/fimmu.2025.1659251.","journal-title":"Front Immunol"},{"key":"957_CR385","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers17172898","volume":"17","author":"S Rafii","year":"2025","unstructured":"Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, et al. Advancing CAR T-Cell therapy in solid tumors: current landscape and future directions. Cancers (Basel). 2025;17:2898. https:\/\/doi.org\/10.3390\/cancers17172898.","journal-title":"Cancers (Basel)"},{"key":"957_CR386","doi-asserted-by":"publisher","first-page":"12","DOI":"10.54844\/cai.2024.0780","volume":"12","author":"GN Kasar","year":"2025","unstructured":"Kasar GN, Rasal PB, Jagtap MN, Surana KR, Mahajan SK, Sonawane DD, et al. CAR T-cell structure, manufacturing, applications, and challenges in the management of communityacquired diseases and disorders. Community Acquir Infect. 2025;12:12. https:\/\/doi.org\/10.54844\/cai.2024.0780.","journal-title":"Community Acquir Infect"},{"issue":"11","key":"957_CR387","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or Dark reality? Mol Ther. 2020;28(11):2320\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015.","journal-title":"Mol Ther"},{"issue":"1","key":"957_CR388","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther. 2025;10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Sig Transduct Target Ther"},{"issue":"4","key":"957_CR389","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","volume":"108","author":"E Donnadieu","year":"2020","unstructured":"Donnadieu E, Dupr\u00e9 L, Pinho LG, Cotta-de-Almeida V. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. J Leukoc Biol. 2020;108(4):1067\u201379. https:\/\/doi.org\/10.1002\/JLB.1MR0520-746R.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"957_CR390","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/curroncol32020079","volume":"32","author":"I Klabukov","year":"2025","unstructured":"Klabukov I, Kabakov AE, Yakimova A, Baranovskii D, Sosin D, Atiakshin D, et al. Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming. Curr Oncol. 2025;32(2):79. https:\/\/doi.org\/10.3390\/curroncol32020079.","journal-title":"Curr Oncol"},{"issue":"1","key":"957_CR391","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imm.70094","volume":"178","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Sun H, Zhao L, Zhao N, Chen Z, He L, et al. Barriers and strategies to enhance CAR-T cell infiltration in solid tumours: a systematic review. Immunology. 2026;178(1):62\u201378. https:\/\/doi.org\/10.1111\/imm.70094.","journal-title":"Immunology"},{"issue":"2","key":"957_CR392","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.cclet.2023.108557","volume":"35","author":"L Guo","year":"2024","unstructured":"Guo L, Ding J, Zhou W. Harnessing bacteria for tumor therapy: current advances and challenges. Chin Chem Lett. 2024;35(2):108557. https:\/\/doi.org\/10.1016\/j.cclet.2023.108557.","journal-title":"Chin Chem Lett"},{"issue":"19","key":"957_CR393","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1097\/CM9.0000000000003803","volume":"138","author":"S Wang","year":"2025","unstructured":"Wang S, Du X, Zhao S, Nie Y. Strategies and challenges in promoting chimeric antigen receptor T cells trafficking and infiltration of solid tumors. Chin Med J. 2025;138(19):2411\u201320. https:\/\/doi.org\/10.1097\/CM9.0000000000003803.","journal-title":"Chin Med J"},{"issue":"1","key":"957_CR394","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"957_CR395","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","journal-title":"Front Pharmacol"},{"issue":"4","key":"957_CR396","doi-asserted-by":"publisher","first-page":"275","DOI":"10.18609\/cgti.2018.028","volume":"4","author":"E Laborda","year":"2018","unstructured":"Laborda E, Young TS. Strategies to control CAR-T cell therapy: perspective on next-generation CARs. Cell Gene Ther Insights. 2018;4(4):275\u201385. https:\/\/doi.org\/10.18609\/cgti.2018.028.","journal-title":"Cell Gene Ther Insights"},{"issue":"1","key":"957_CR397","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"957_CR398","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44272-025-00044-0","volume":"4","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Han W. Management of cytokine release syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clin Cancer Bull. 2025;4(1):1\u20139. https:\/\/doi.org\/10.1007\/s44272-025-00044-0.","journal-title":"Clin Cancer Bull"},{"issue":"2","key":"957_CR399","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"957_CR400","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma. JCO. 2015;33(15):1688\u201396. https:\/\/doi.org\/10.1200\/JCO.2014.58.0225.","journal-title":"JCO"},{"issue":"18","key":"957_CR401","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0428.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"957_CR402","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468\u201379. https:\/\/doi.org\/10.1007\/s11427-016-5023-8.","journal-title":"Sci China Life Sci"},{"key":"957_CR403","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"issue":"1","key":"957_CR404","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O\u2019Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.029.","journal-title":"Gastroenterology"},{"issue":"10","key":"957_CR405","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy. 2020;22(10):573\u201380. https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.088.","journal-title":"Cytotherapy"},{"issue":"15","key":"957_CR406","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3259.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"957_CR407","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional Mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0407.","journal-title":"Cancer Discov"},{"issue":"6","key":"957_CR408","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"issue":"4","key":"957_CR409","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"issue":"6","key":"957_CR410","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880\u201394. https:\/\/doi.org\/10.1038\/s43018-024-00749-6.","journal-title":"Nat Cancer"},{"issue":"35","key":"957_CR411","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: a first-in-human phase I study of Systemically administered B7-H3 chimeric antigen receptor T cells for patients with Relapsed\/Refractory solid tumors. JCO. 2024;42(35):4163\u201372. https:\/\/doi.org\/10.1200\/JCO.23.02229.","journal-title":"JCO"},{"key":"957_CR412","doi-asserted-by":"publisher","unstructured":"Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. J Immunother Cancer. 2024;12(5):e008659. https:\/\/doi.org\/10.1136\/jitc-2023-008659.","DOI":"10.1136\/jitc-2023-008659"},{"issue":"5","key":"957_CR413","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142\u201348. https:\/\/doi.org\/10.1038\/cgt.2016.14.","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"957_CR414","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1152\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"957_CR415","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin Cancer Res. 2018;24(1):95\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2041.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"957_CR416","first-page":"106","volume":"8","author":"Y Han","year":"2018","unstructured":"Han Y, Liu C, Li G, Li J, Lv X, Shi H, et al. Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res. 2018;8(1):106\u201319.","journal-title":"Am J Cancer Res"},{"key":"957_CR417","doi-asserted-by":"publisher","unstructured":"Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722. https:\/\/doi.org\/10.1080\/2162402X.2017.1284722.","DOI":"10.1080\/2162402X.2017.1284722"},{"key":"957_CR418","doi-asserted-by":"publisher","unstructured":"Wallstabe L, G\u00f6ttlich C, Nelke LC, K\u00fchnemundt J, Schwarz T, Nerreter T, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019;4(18). https:\/\/doi.org\/10.1172\/jci.insight.126345.","DOI":"10.1172\/jci.insight.126345"},{"issue":"1","key":"957_CR419","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118. https:\/\/doi.org\/10.1186\/s13045-021-01128-9.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"957_CR420","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","volume":"39","author":"LL Lu","year":"2023","unstructured":"Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, et al. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol Toxicol. 2023;39(6):3101\u201319. https:\/\/doi.org\/10.1007\/s10565-023-09821-w.","journal-title":"Cell Biol Toxicol"},{"key":"957_CR421","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cellimm.2023.104760","volume":"391-392","author":"A Wang","year":"2023","unstructured":"Wang A, Lv T, Song Y. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. Cellular Immunol. 2023;391-392:391\u20132. 104760. https:\/\/doi.org\/10.1016\/j.cellimm.2023.104760.","journal-title":"Cellular Immunol"},{"issue":"23","key":"957_CR422","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","volume":"30","author":"AM Barrett","year":"2024","unstructured":"Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, Hatke AL, et al. Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers. Clin Cancer Res. 2024;30(23):5413\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1853.","journal-title":"Clin Cancer Res"},{"key":"957_CR423","doi-asserted-by":"publisher","unstructured":"Shabaneh TB, Stevens AR, Stull SM, Shimp KR, Seaton BW, Gad EA, et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J Immunother Cancer. 2024;12(2):e008566. https:\/\/doi.org\/10.1136\/jitc-2023-008566.","DOI":"10.1136\/jitc-2023-008566"},{"issue":"5","key":"957_CR424","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/cells10051170","volume":"10","author":"M Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy M, Gerhardt L, Maleki Vareki S. Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy. Cells. 2021;10(5):1170. https:\/\/doi.org\/10.3390\/cells10051170.","journal-title":"Cells"},{"issue":"6","key":"957_CR425","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R. Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics. 2025;15(6):2159\u201384. https:\/\/doi.org\/10.7150\/thno.105276.","journal-title":"Theranostics"},{"key":"957_CR426","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W. Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. J Control Release. 2025;382:113664. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113664.","journal-title":"J Control Release"},{"issue":"1","key":"957_CR427","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"NMF Abdalsalam","year":"2024","unstructured":"Abdalsalam NMF, Ibrahim A, Saliu MA, Liu TM, Wan X, Yan D. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal. 2024;22(1):612. https:\/\/doi.org\/10.1186\/s12964-024-01995-y.","journal-title":"Cell Commun Signal"},{"key":"957_CR428","doi-asserted-by":"publisher","first-page":"1320807","DOI":"10.3389\/fbioe.2023.1320807","volume":"11","author":"Y Tang","year":"2024","unstructured":"Tang Y, Yang X, Hu H, Jiang H, Xiong W, Mei H, et al. Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques. Front Bioeng Biotechnol. 2024;11:1320807. https:\/\/doi.org\/10.3389\/fbioe.2023.1320807.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"957_CR429","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","volume":"40","author":"L Cherkassky","year":"2022","unstructured":"Cherkassky L, Hou Z, Amador-Molina A, Adusumilli PS. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell. 2022;40(6):569\u201374. https:\/\/doi.org\/10.1016\/j.ccell.2022.04.006.","journal-title":"Cancer Cell"},{"issue":"7","key":"957_CR430","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-Cells for cancer therapy. Cancers (Basel). 2017;9(7):92. https:\/\/doi.org\/10.3390\/cancers9070092.","journal-title":"Cancers (Basel)"},{"key":"957_CR431","doi-asserted-by":"publisher","unstructured":"Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8(14):eabn 8264. https:\/\/doi.org\/10.1126\/sciadv.abn8264.","DOI":"10.1126\/sciadv.abn8264"},{"key":"957_CR432","doi-asserted-by":"publisher","unstructured":"Qin J, Jiang Z. Ultrasound-responsive Calcium Copper phosphate nanomaterials induce tumor cell death via the synergistic release of Copper and Calcium. IJMS. 2026;27(4):2016 p. https:\/\/doi.org\/10.3390\/ijms27042016.","DOI":"10.3390\/ijms27042016"},{"key":"957_CR433","doi-asserted-by":"publisher","first-page":"106329","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharmacological Res. 2022;182:106329. https:\/\/doi.org\/10.1016\/j.phrs.2022.106329.","journal-title":"Pharmacological Res"},{"issue":"1","key":"957_CR434","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","volume":"8","author":"S Park","year":"2024","unstructured":"Park S, Maus MV, Choi BD. CAR-T cell therapy for the treatment of adult high-grade gliomas. NPJ Precis Onc. 2024;8(1):279. https:\/\/doi.org\/10.1038\/s41698-024-00753-0.","journal-title":"NPJ Precis Onc"},{"issue":"5","key":"957_CR435","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/cas.70023","volume":"116","author":"Y Ito","year":"2025","unstructured":"Ito Y, Suzuki T, Shimomura M, Takenouchi K, Ohnuki K, Shoda K, et al. Feasibility of intratumoral administration with EPHB4-CAR-T cells for the treatment of Oral squamous cell carcinoma. Cancer Sci. 2025;116(5):1227\u201338. https:\/\/doi.org\/10.1111\/cas.70023.","journal-title":"Cancer Sci"},{"issue":"7","key":"957_CR436","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1039\/D3NR05768B","volume":"16","author":"Y Lin","year":"2024","unstructured":"Lin Y, Chen Y, Luo Z, Wu YL. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment. Nanoscale. 2024;16(7):3226\u201342. https:\/\/doi.org\/10.1039\/D3NR05768B.","journal-title":"Nanoscale"},{"issue":"5","key":"957_CR437","doi-asserted-by":"publisher","first-page":"742","DOI":"10.21147\/j.issn.1000-9604.2025.05.07","volume":"37","author":"S Huang","year":"2025","unstructured":"Huang S, Zhao Y, Shen J. Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy. Chin J Cancer Res. 2025;37(5):742\u201358.","journal-title":"Chin J Cancer Res"},{"issue":"21","key":"957_CR438","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1182\/bloodadvances.2025017507","volume":"9","author":"S Fiorenza","year":"2025","unstructured":"Fiorenza S, Dowling MR. ctDNA MRD after CAR-T. Blood Adv. 2025;9(21):5568\u201370. https:\/\/doi.org\/10.1182\/bloodadvances.2025017507.","journal-title":"Blood Adv"},{"key":"957_CR439","doi-asserted-by":"publisher","first-page":"1728163","DOI":"10.3389\/fimmu.2025.1728163","volume":"16","author":"J Han","year":"2026","unstructured":"Han J, Yang Z, Zhao H. Lung cancer immunotherapy in 2025: Where we stand and what comes next? Front Immunol. 2026;16:1728163. https:\/\/doi.org\/10.3389\/fimmu.2025.1728163.","journal-title":"Front Immunol"},{"key":"957_CR440","doi-asserted-by":"publisher","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","DOI":"10.1002\/smll.202304378"},{"key":"957_CR441","doi-asserted-by":"publisher","unstructured":"Bimbo JF, van Diest E, Murphy DE, Ashoti A, Evers MJW, Narayanavari SA, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025;13(7):e011759. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","DOI":"10.1136\/jitc-2025-011759"},{"key":"957_CR442","doi-asserted-by":"publisher","first-page":"1165576","DOI":"10.3389\/fimmu.2023.1165576","volume":"14","author":"YT Qin","year":"2023","unstructured":"Qin YT, Li YP, He XW, Wang X, Li WY, Zhang YK. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Front Immunol. 2023;14:1165576. https:\/\/doi.org\/10.3389\/fimmu.2023.1165576.","journal-title":"Front Immunol"},{"key":"957_CR443","doi-asserted-by":"publisher","first-page":"122580","DOI":"10.1016\/j.biomaterials.2024.122580","volume":"308","author":"S Pandit","year":"2024","unstructured":"Pandit S, Agarwalla P, Song F, Jansson A, Dotti G, Brudno Y. Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials. 2024;308:122580. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122580.","journal-title":"Biomaterials"},{"key":"957_CR444","doi-asserted-by":"publisher","unstructured":"Zhuang J, Gong H, Zhou J, Zhang Q, Gao W, Fang RH, et al. Targeted gene silencing in vivo by platelet membrane\u2013coated metal-organic framework nanoparticles. Sci Adv. 2020;6(13):eaaz 6108. https:\/\/doi.org\/10.1126\/sciadv.aaz6108.","DOI":"10.1126\/sciadv.aaz6108"},{"key":"957_CR445","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2015.10.046","volume":"76","author":"J Li","year":"2016","unstructured":"Li J, Ai Y, Wang L, Bu P, Sharkey CC, Wu Q, et al. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials. 2016;76:52\u201365. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.10.046.","journal-title":"Biomaterials"},{"issue":"7","key":"957_CR446","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.matt.2023.04.026","volume":"6","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang Y, Yao Y, Wang S, Zhang Y, Dotti G, et al. T cell-mimicking platelet-drug conjugates. Matter. 2023;6(7):2340\u201355. https:\/\/doi.org\/10.1016\/j.matt.2023.04.026.","journal-title":"Matter"},{"issue":"4","key":"957_CR447","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/pharmaceutics16040531","volume":"16","author":"S Zhang","year":"2024","unstructured":"Zhang S, Zhang X, Gao H, Zhang X, Sun L, Huang Y, et al. Cell membrane-coated biomimetic nanoparticles in cancer treatment. Pharmaceutics. 2024;16(4):531. https:\/\/doi.org\/10.3390\/pharmaceutics16040531.","journal-title":"Pharmaceutics"},{"issue":"5","key":"957_CR448","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41571-026-01122-5","volume":"23","author":"Y Chen","year":"2026","unstructured":"Chen Y, Wolter T, Gu Z, Hu Q. Engineering platelets as cancer therapeutics. Nat Rev Clin Oncol. 2026;23(5):323\u201340. https:\/\/doi.org\/10.1038\/s41571-026-01122-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"957_CR449","doi-asserted-by":"publisher","first-page":"120395","DOI":"10.1016\/j.ijpharm.2021.120395","volume":"598","author":"SS Kunde","year":"2021","unstructured":"Kunde SS, Wairkar S. Platelet membrane camouflaged nanoparticles: Biomimetic architecture for targeted therapy. Int J Multiling Pharm. 2021;598:120395. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120395.","journal-title":"Int J Multiling Pharm"},{"issue":"9","key":"957_CR450","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038\u201347. https:\/\/doi.org\/10.1038\/s41551-021-00712-1.","journal-title":"Nat Biomed Eng"},{"key":"957_CR451","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2022.01.004","volume":"172","author":"H Han","year":"2022","unstructured":"Han H, B\u00e1rtolo R, Li J, Shahbazi MA, Santos HA. Biomimetic platelet membrane-coated nanoparticles for targeted therapy. Eur J Criminol Pharm Biopharmaceutics. 2022;172:1\u201315. https:\/\/doi.org\/10.1016\/j.ejpb.2022.01.004.","journal-title":"Eur J Criminol Pharm Biopharmaceutics"},{"issue":"4","key":"957_CR452","doi-asserted-by":"publisher","first-page":"100225","DOI":"10.1016\/j.celbio.2025.100225","volume":"2","author":"Q Wu","year":"2026","unstructured":"Wu Q, Zhu C, Li Y, Zhang B, Zheng H, Wang F, et al. Adoptive platelet transfer for metastasis treatment via circulating tumor cells targeted conveyance of oncolytic virus. Cell Biomater. 2026;2(4):100225. https:\/\/doi.org\/10.1016\/j.celbio.2025.100225.","journal-title":"Cell Biomater"},{"key":"957_CR453","doi-asserted-by":"publisher","unstructured":"Lutz MS, Klimovich B, Maurer S, Heitmann JS, M\u00e4rklin M, Zekri L, et al. Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies. J Immunother Cancer. 2022;10(2):e003655. https:\/\/doi.org\/10.1136\/jitc-2021-003655.","DOI":"10.1136\/jitc-2021-003655"},{"issue":"1","key":"957_CR454","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s40425-019-0804-9","volume":"7","author":"A Torres Chavez","year":"2019","unstructured":"Torres Chavez A, Mk M, Canestrari E, Dann CT, Ramos CA, Lulla P, et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019;7(1):330.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"957_CR455","doi-asserted-by":"publisher","first-page":"100051","DOI":"10.1016\/j.bneo.2024.100051","volume":"2","author":"T Jo","year":"2025","unstructured":"Jo T, Yoshihara K, Ri M, Tsukada N, Mimura N, Fujii K, et al. Low platelet counts and low CD4\/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma. Blood Neoplasia. 2025;2(1):100051. https:\/\/doi.org\/10.1016\/j.bneo.2024.100051.","journal-title":"Blood Neoplasia"},{"issue":"2","key":"957_CR456","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10555-017-9682-0","volume":"36","author":"DG Menter","year":"2017","unstructured":"Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet \u201cfirst responders\u201d in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017;36(2):199\u2013213. https:\/\/doi.org\/10.1007\/s10555-017-9682-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"957_CR457","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/jth.14976","volume":"18","author":"S Patmore","year":"2020","unstructured":"Patmore S, Dhami SPS, O\u2019Sullivan JM. Von Willebrand factor and cancer; metastasis and coagulopathies. J Thromb Haemostasis. 2020;18(10):2444\u201356. https:\/\/doi.org\/10.1111\/jth.14976.","journal-title":"J Thromb Haemostasis"},{"key":"957_CR458","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fphar.2020.00024","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Sun M, Wang J, Wang C, Sun Y. Cell membrane-Camouflaged nanocarriers for cancer diagnostic and therapeutic. Front Pharmacol. 2020;11:24. https:\/\/doi.org\/10.3389\/fphar.2020.00024.","journal-title":"Front Pharmacol"},{"issue":"1","key":"957_CR459","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/s41467-021-22311-z","volume":"12","author":"B Bahmani","year":"2021","unstructured":"Bahmani B, Gong H, Luk BT, Haushalter KJ, DeTeresa E, Previti M, et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat Commun. 2021;12(1):1999. https:\/\/doi.org\/10.1038\/s41467-021-22311-z.","journal-title":"Nat Commun"},{"key":"957_CR460","doi-asserted-by":"publisher","unstructured":"Zhang K, Li H, Ma Z, Zhong W, Yu Y, Zhao Y. Engineered platelets for cancer therapy. Aggregate. 2025;6(2):e704. https:\/\/doi.org\/10.1002\/agt2.704.","DOI":"10.1002\/agt2.704"},{"key":"957_CR461","doi-asserted-by":"publisher","first-page":"10151","DOI":"10.2147\/IJN.S285952","volume":"15","author":"W Pei","year":"2020","unstructured":"Pei W, Huang B, Chen S, Wang L, Xu Y, Niu C. Platelet-mimicking drug delivery nanoparticles for enhanced chemo-photothermal therapy of breast cancer. IJN. 2020: 10151\u201367. 15 https:\/\/doi.org\/10.2147\/IJN.S285952.","journal-title":"IJN"},{"issue":"2","key":"957_CR462","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","volume":"75","author":"Z Zhang","year":"2026","unstructured":"Zhang Z, Cui D, Wang H, Wu L, Liu X. Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunol Immunother. 2026;75(2):37. https:\/\/doi.org\/10.1007\/s00262-025-04278-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"957_CR463","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/acs.nanolett.1c00168","volume":"21","author":"B Li","year":"2021","unstructured":"Li B, Chu T, Wei J, Zhang Y, Qi F, Lu Z, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588\u201395. https:\/\/doi.org\/10.1021\/acs.nanolett.1c00168.","journal-title":"Nano Lett"},{"issue":"1","key":"957_CR464","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12951-019-0494-y","volume":"17","author":"H Wang","year":"2019","unstructured":"Wang H, Wu J, Williams GR, Fan Q, Niu S, Wu J, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnol. 2019;17(1):60. https:\/\/doi.org\/10.1186\/s12951-019-0494-y.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"957_CR465","doi-asserted-by":"publisher","first-page":"460","DOI":"10.14744\/ejmo.2024.80504","volume":"8","author":"Y Ergun","year":"2024","unstructured":"Ergun Y. Neoadjuvant or perioperative immunotherapy in resectable non-small cell lung cancer: pooled analysis of subgroups in randomized controlled trial. EJMO. 2024;8(4):460\u201370. https:\/\/doi.org\/10.14744\/ejmo.2024.80504.","journal-title":"EJMO"},{"key":"957_CR466","doi-asserted-by":"publisher","unstructured":"Liao Z, Jiang J, Wu W, Shi J, Wang Y, Yao Y, et al. Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor. Natl Sci Rev. 2024;11(4):nwae018. https:\/\/doi.org\/10.1093\/nsr\/nwae018.","DOI":"10.1093\/nsr\/nwae018"},{"key":"957_CR467","doi-asserted-by":"publisher","unstructured":"Raskov H, Orhan A, Agerb\u00e6k M\u00d8, G\u00f6genur I. The impact of platelets on the metastatic potential of tumour cells. Heliyon. 2024;10(14):e34361. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34361.","DOI":"10.1016\/j.heliyon.2024.e34361"},{"issue":"8","key":"957_CR468","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jcyt.2024.03.006","volume":"26","author":"F Mo","year":"2024","unstructured":"Mo F, Tsai CT, Zheng R, Cheng C, Heslop HE, Brenner MK, et al. Human platelet lysate enhances in vivo activity of CAR-V\u03b42 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024;26(8):858\u201368. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.006.","journal-title":"Cytotherapy"},{"issue":"45","key":"957_CR469","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1039\/C8TB02301H","volume":"6","author":"Z Li","year":"2018","unstructured":"Li Z, Hu S, Cheng K. Platelets and their biomimetics for regenerative medicine and cancer therapies. J Mater Chem B. 2018;6(45):7354\u201365. https:\/\/doi.org\/10.1039\/C8TB02301H.","journal-title":"J Mater Chem B"},{"issue":"24","key":"957_CR470","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"key":"957_CR471","doi-asserted-by":"publisher","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021;11:763790. https:\/\/doi.org\/10.3389\/fonc.2021.763790.","journal-title":"Front Oncol"},{"key":"957_CR472","doi-asserted-by":"publisher","first-page":"640578","DOI":"10.3389\/fimmu.2021.640578","volume":"12","author":"L Schmied","year":"2021","unstructured":"Schmied L, H\u00f6glund P, Meinke S. Platelet-mediated protection of cancer cells from immune surveillance \u2013 possible implications for cancer immunotherapy. Front Immunol. 2021;12:640578. https:\/\/doi.org\/10.3389\/fimmu.2021.640578.","journal-title":"Front Immunol"},{"key":"957_CR473","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fcvm.2017.00067","volume":"4","author":"EC Lee","year":"2017","unstructured":"Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm. Front. Cardiovasc. Med. 2017;4:67. https:\/\/doi.org\/10.3389\/fcvm.2017.00067.","journal-title":"Front. Cardiovasc. Med"},{"issue":"2","key":"957_CR474","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/bjh.19619","volume":"205","author":"E Galli","year":"2024","unstructured":"Galli E, Sor\u00e0 F, Rossi E. Coagulopathy in CAR-T: Critical concern or mere blip? Br J Haematol. 2024;205(2):409\u201310. https:\/\/doi.org\/10.1111\/bjh.19619.","journal-title":"Br J Haematol"},{"issue":"7","key":"957_CR475","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41417-025-00915-7","volume":"32","author":"D Tang","year":"2025","unstructured":"Tang D, Kang R. Platelet activation: a barrier to effective antitumor immunity. Cancer Gene Ther. 2025;32(7):741\u201343. https:\/\/doi.org\/10.1038\/s41417-025-00915-7.","journal-title":"Cancer Gene Ther"},{"key":"957_CR476","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2020.08.030","volume":"328","author":"S Wang","year":"2020","unstructured":"Wang S, Wang R, Meng N, Guo H, Wu S, Wang X, et al. Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy. J Control Release. 2020;328:78\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2020.08.030.","journal-title":"J Control Release"},{"issue":"17","key":"957_CR477","doi-asserted-by":"publisher","first-page":"21438","DOI":"10.1021\/acsami.3c18402","volume":"16","author":"R Hua","year":"2024","unstructured":"Hua R, Li M, Lin Q, Dong M, Gong X, Lin Z, et al. Platelet membrane-coated r-SAK improves thrombolytic efficacy by targeting thrombus. ACS Appl Mater Interface. 2024;16(17):21438\u201349. https:\/\/doi.org\/10.1021\/acsami.3c18402.","journal-title":"ACS Appl Mater Interface"},{"key":"957_CR478","doi-asserted-by":"publisher","first-page":"122670","DOI":"10.1016\/j.biomaterials.2024.122670","volume":"311","author":"H Xiao","year":"2024","unstructured":"Xiao H, Meng X, Songtao L, Li Z, Fang S, Wang Y, et al. Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology. Biomaterials. 2024;311:122670.","journal-title":"Biomaterials"},{"issue":"6","key":"957_CR479","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MOH.0000000000000888","volume":"32","author":"RP Jackman","year":"2025","unstructured":"Jackman RP, Thomas KA. Immune response to platelet transfusions. Curr Opin Hematol. 2025;32(6):357\u201363. https:\/\/doi.org\/10.1097\/MOH.0000000000000888.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"957_CR480","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000151350","volume":"35","author":"V Kiefel","year":"2008","unstructured":"Kiefel V. Reactions induced by platelet transfusions. Transfus Med Hemother. 2008;35(5):354\u201358. https:\/\/doi.org\/10.1159\/000151350.","journal-title":"Transfus Med Hemother"},{"issue":"21","key":"957_CR481","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","volume":"5","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud A, Craig J, Baird J, Spiegel J, Muffly L, Zehnder J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5(21):4465\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2021004716.","journal-title":"Blood Adv"},{"issue":"7","key":"957_CR482","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","volume":"22","author":"P Bindal","year":"2024","unstructured":"Bindal P, Patell R, Chiasakul T, Lauw MN, Ko A, Wang TF, et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemostasis. 2024;22(7):2071\u201380. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.021.","journal-title":"J Thromb Haemostasis"},{"issue":"24","key":"957_CR483","doi-asserted-by":"publisher","first-page":"11014","DOI":"10.1073\/pnas.0811529107","volume":"107","author":"PN Zawaneh","year":"2010","unstructured":"Zawaneh PN, Singh SP, Padera RF, Henderson PW, Spector JA, Putnam D. Design of an injectable synthetic and biodegradable surgical biomaterial. Proc Natl Acad Sci USA. 2010;107(24):11014\u201319. https:\/\/doi.org\/10.1073\/pnas.0811529107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"957_CR484","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12951-025-03572-y","volume":"23","author":"S Yuan","year":"2025","unstructured":"Yuan S, Hu D, Gao D, Butch CJ, Wang Y, Zheng H, et al. Recent advances of engineering cell membranes for nanomedicine delivery across the blood\u2013brain barrier. J Nanobiotechnol. 2025;23(1):493. https:\/\/doi.org\/10.1186\/s12951-025-03572-y.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"957_CR485","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408\u201322. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0084.","journal-title":"Blood Cancer Discov"},{"key":"957_CR486","unstructured":"Agency EM. Nanotechnology-based medicinal products for human use: EU horizon scanning report. 2025. European Medicines Agency Amsterdam."},{"issue":"3","key":"957_CR487","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s13346-022-01252-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu H, Su YY, Jiang XC, Gao JQ. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Deliv Transl Res. 2023;13(3):716\u201337. https:\/\/doi.org\/10.1007\/s13346-022-01252-0.","journal-title":"Drug Deliv Transl Res"},{"key":"957_CR488","doi-asserted-by":"publisher","unstructured":"Zewail MB, Yang G, Fan Y, Hui Y, Zhao CX, Liu Y. Cell membrane-coated lipid nanoparticles for drug delivery. Aggregate. 2025;6(7):e70054. https:\/\/doi.org\/10.1002\/agt2.70054.","DOI":"10.1002\/agt2.70054"},{"key":"957_CR489","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.vesic.2023.100029","volume":"2","author":"K Cheng","year":"2023","unstructured":"Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracell Vesicle. 2023;2:100029. https:\/\/doi.org\/10.1016\/j.vesic.2023.100029.","journal-title":"Extracell Vesicle"},{"issue":"5","key":"957_CR490","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s41669-023-00427-w","volume":"7","author":"J Laermans","year":"2023","unstructured":"Laermans J, Van Remoortel H, Scheers H, Avau B, Georgsen J, Nahirniak S, et al. Cost effectiveness of different platelet preparation, storage, selection and dosing methods in platelet transfusion: a systematic review. Pharmacoeconomics Open. 2023;7(5):679\u2013708. https:\/\/doi.org\/10.1007\/s41669-023-00427-w.","journal-title":"Pharmacoeconomics Open"},{"issue":"12","key":"957_CR491","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.3390\/ijms21124541","volume":"21","author":"E Gianazza","year":"2020","unstructured":"Gianazza E, Brioschi M, Baetta R, Mallia A, Banfi C, Tremoli E. Platelets in healthy and disease states: from biomarkers Discovery to drug targets Identification by Proteomics. IJMS. 2020;21(12):4541. https:\/\/doi.org\/10.3390\/ijms21124541.","journal-title":"IJMS"},{"issue":"4","key":"957_CR492","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0974-2077.150734","volume":"7","author":"R Dhurat","year":"2014","unstructured":"Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author\u2032s perspective. J Cutan Aesthet Surg. 2014;7(4):189\u201397. https:\/\/doi.org\/10.4103\/0974-2077.150734.","journal-title":"J Cutan Aesthet Surg"},{"issue":"1","key":"957_CR493","doi-asserted-by":"publisher","first-page":"2237134","DOI":"10.1080\/09537104.2023.2237134","volume":"34","author":"YW Wu","year":"2023","unstructured":"Wu YW, Lee DY, Lu YL, Delila L, Nebie O, Barro L, et al. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization. Platelets. 2023;34(1):2237134. https:\/\/doi.org\/10.1080\/09537104.2023.2237134.","journal-title":"Platelets"},{"key":"957_CR494","doi-asserted-by":"publisher","unstructured":"Zahid AA, Patel M, Paul A. Cell membrane-engineered biomimetic nanoparticles: exploiting the nano-biointerface for medical applications. Cell Biomater. 2026;100444. https:\/\/doi.org\/10.1016\/j.celbio.2026.100444.","DOI":"10.1016\/j.celbio.2026.100444"},{"issue":"1","key":"957_CR495","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12929-023-00972-w","volume":"30","author":"T Burnouf","year":"2023","unstructured":"Burnouf T, Chou ML, Lundy DJ, Chuang EY, Tseng CL, Goubran H. Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery. J Biomed Sci. 2023;30(1):79. https:\/\/doi.org\/10.1186\/s12929-023-00972-w.","journal-title":"J Biomed Sci"},{"key":"957_CR496","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.jlb.2024.100278","volume":"6","author":"A Thakur","year":"2024","unstructured":"Thakur A, Rai D. Global requirements for manufacturing and validation of clinical grade extracellular vesicles. J Sport Hist Liquid Biopsy. 2024;6:100278. https:\/\/doi.org\/10.1016\/j.jlb.2024.100278.","journal-title":"J Sport Hist Liquid Biopsy"},{"issue":"11","key":"957_CR497","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s13346-023-01359-y","volume":"13","author":"M van der Zee","year":"2023","unstructured":"van der Zee M, de Vries C, Masa M, Morales M, Rayo M, Hegger I. Regulatory aspects of a nanomaterial for imaging therapeutic cells. Drug Deliv Transl Res. 2023;13(11):2693\u2013703. https:\/\/doi.org\/10.1007\/s13346-023-01359-y.","journal-title":"Drug Deliv Transl Res"},{"key":"957_CR498","doi-asserted-by":"publisher","unstructured":"Humbert C, Cordier C, Drut I, Hamrick M, Wong J, Bellamy V, et al. GMP-Compliant process for the manufacturing of an extracellular vesicles-enriched Secretome product derived from Cardiovascular progenitor cells suitable for a phase I clinical trial. J Extracell Vesicle. 2025;14(8):e70145. https:\/\/doi.org\/10.1002\/jev2.70145.","DOI":"10.1002\/jev2.70145"},{"issue":"2","key":"957_CR499","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1039\/D5BM00511F","volume":"14","author":"D Coradduzza","year":"2026","unstructured":"Coradduzza D, Vecciu B, Cadoni MPL, Azara EG, Carru C, Medici S. Platelet-derived membranes as biomimetic interfaces for engineering functional nanocarriers in targeted drug delivery and diagnostics: a systematic review. Biomater Sci. 2026;14(2):377\u201392. https:\/\/doi.org\/10.1039\/D5BM00511F.","journal-title":"Biomater Sci"},{"key":"957_CR500","doi-asserted-by":"publisher","first-page":"122478","DOI":"10.1016\/j.biomaterials.2024.122478","volume":"306","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Xu L, Kang Y, Cheng Q, He Y, Ji X. Platelet-derived drug delivery systems: pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond. Biomaterials. 2024;306:122478. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122478.","journal-title":"Biomaterials"},{"key":"957_CR501","doi-asserted-by":"publisher","unstructured":"Jia Y, Wang X, Li L, Li F, Zhang J, Liang XJ. Lipid nanoparticles optimized for targeting and release of nucleic acid. Adv Mater. 2024;36(4):e2305300. https:\/\/doi.org\/10.1002\/adma.202305300.","DOI":"10.1002\/adma.202305300"},{"key":"957_CR502","doi-asserted-by":"publisher","first-page":"103897","DOI":"10.1016\/j.cis.2026.103897","volume":"354","author":"D Zhi","year":"2026","unstructured":"Zhi D, Halemaimaiti A, Dai B, Li H, Wang H, Zhang Z, et al. Advances in lipids design for LNP-mediated DNA and RNA delivery. Adv Colloid Interface Sci. 2026;354:103897. https:\/\/doi.org\/10.1016\/j.cis.2026.103897.","journal-title":"Adv Colloid Interface Sci"},{"issue":"4","key":"957_CR503","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater. 2023;8(4):282\u2013300. https:\/\/doi.org\/10.1038\/s41578-022-00529-7.","journal-title":"Nat Rev Mater"},{"key":"957_CR504","doi-asserted-by":"publisher","first-page":"125899","DOI":"10.1016\/j.ijpharm.2025.125899","volume":"682","author":"A Pareek","year":"2025","unstructured":"Pareek A, Bhatt B, Parmar V, Alasiri G, Alsaidan OA, Kapoor DU, et al. pH-sensitive hydrogels for breast cancer therapy: targeted drug delivery and controlled release approaches. Int J Multiling Pharm. 2025;682:125899. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125899.","journal-title":"Int J Multiling Pharm"},{"issue":"13","key":"957_CR505","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.7150\/thno.99257","volume":"14","author":"W Liu","year":"2024","unstructured":"Liu W, Cheng G, Cui H, Tian Z, Li B, Han Y, et al. Theoretical basis, state and challenges of living cell-based drug delivery systems. Theranostics. 2024;14(13):5152\u201383. https:\/\/doi.org\/10.7150\/thno.99257.","journal-title":"Theranostics"},{"issue":"4","key":"957_CR506","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/ab500179h","volume":"1","author":"Y Su","year":"2015","unstructured":"Su Y, Xie Z, Kim GB, Dong C, Yang J. Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng. 2015;1(4):201\u201317. https:\/\/doi.org\/10.1021\/ab500179h.","journal-title":"ACS Biomater. Sci. Eng"},{"key":"957_CR507","doi-asserted-by":"publisher","unstructured":"Chen Y, Qin D, Zou J, Li X, Guo XD, Tang Y, et al. Living leukocyte-based drug delivery systems. Adv Mater. 2023;35(17):e2207787. https:\/\/doi.org\/10.1002\/adma.202207787.","DOI":"10.1002\/adma.202207787"},{"issue":"1","key":"957_CR508","doi-asserted-by":"publisher","first-page":"2425156","DOI":"10.1080\/10717544.2024.2425156","volume":"31","author":"A He","year":"2024","unstructured":"He A, Huang Y, Cao C, Li X. Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles. Drug Deliv. 2024;31(1):2425156. https:\/\/doi.org\/10.1080\/10717544.2024.2425156.","journal-title":"Drug Deliv"},{"issue":"8","key":"957_CR509","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.3390\/curroncol30080540","volume":"30","author":"E Sandbank","year":"2023","unstructured":"Sandbank E, Eckerling A, Margalit A, Sorski L, Ben-Eliyahu S. Immunotherapy during the immediate perioperative period: a promising approach against metastatic disease. Curr Oncol. 2023;30(8):7450\u201377. https:\/\/doi.org\/10.3390\/curroncol30080540.","journal-title":"Curr Oncol"},{"issue":"1","key":"957_CR510","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jfb16010015","volume":"16","author":"L Xie","year":"2025","unstructured":"Xie L, Gan F, Hu Y, Zheng Y, Lan J, Liu Y, et al. From blood to therapy: the revolutionary application of platelets in cancer-targeted drug delivery. JFB. 2025;16(1):15. https:\/\/doi.org\/10.3390\/jfb16010015.","journal-title":"JFB"},{"key":"957_CR511","doi-asserted-by":"crossref","unstructured":"Logun MT, Begley SL, Hicks K, Park J, Zhang L, Binder ZA, et al. CAR-T cells locally delivered in porcine decellularized matrix hydrogels enhance survival in post-resection glioblastoma. bioRxiv. 2025.02.11.637648.","DOI":"10.1101\/2025.02.11.637648"},{"issue":"9","key":"957_CR512","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/1759-7714.13942","volume":"12","author":"J Ni","year":"2021","unstructured":"Ni J, Huang M, Zhang L, Wu N, Bai CX, Chen LA, et al. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thorac Cancer. 2021;12(9):1469\u201388. https:\/\/doi.org\/10.1111\/1759-7714.13942.","journal-title":"Thorac Cancer"},{"issue":"1","key":"957_CR513","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13741-023-00315-1","volume":"12","author":"A Dabo-Trubelja","year":"2023","unstructured":"Dabo-Trubelja A, Gottumukkala V. Review of cancer therapies for the perioperative physician. Perioper Med. 2023;12(1):25. https:\/\/doi.org\/10.1186\/s13741-023-00315-1.","journal-title":"Perioper Med"},{"key":"957_CR514","doi-asserted-by":"publisher","first-page":"1261312","DOI":"10.3389\/fphar.2023.1261312","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, He R, Chen X, Jiang L, Wang F. Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges. Front Pharmacol. 2023;14:1261312. https:\/\/doi.org\/10.3389\/fphar.2023.1261312.","journal-title":"Front Pharmacol"},{"key":"957_CR515","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.conctc.2024.101329","volume":"40","author":"JJZ Liao","year":"2024","unstructured":"Liao JJZ, Asatiani E, Liu Q, Hou K. Three steps toward dose optimization for oncology dose finding. Contemp Clin Trials Commun. 2024;40:101329. https:\/\/doi.org\/10.1016\/j.conctc.2024.101329.","journal-title":"Contemp Clin Trials Commun"},{"key":"957_CR516","doi-asserted-by":"publisher","unstructured":"Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose\u2013response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer. 2022;10(12):e005678. https:\/\/doi.org\/10.1136\/jitc-2022-005678.","DOI":"10.1136\/jitc-2022-005678"},{"issue":"6","key":"957_CR517","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/sj.bjp.0706386","volume":"146","author":"A Radomski","year":"2005","unstructured":"Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146(6):882\u201393. https:\/\/doi.org\/10.1038\/sj.bjp.0706386.","journal-title":"Br J Pharmacol"},{"key":"957_CR518","doi-asserted-by":"publisher","unstructured":"Restle D, Amador-Molina A, Misawa K, Banerjee S, Ku G, Adusumilli PS. Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396). J Immunother Cancer. 2025;13(9):e012292. https:\/\/doi.org\/10.1136\/jitc-2025-012292.","DOI":"10.1136\/jitc-2025-012292"},{"issue":"18","key":"957_CR519","doi-asserted-by":"publisher","first-page":"17653","DOI":"10.1021\/acsnano.5c01366","volume":"19","author":"S Lei","year":"2025","unstructured":"Lei S, Gao Y, Wang K, Wu S, Zhu M, Chen X, et al. An implantable Double-layered spherical scaffold depositing gene and cell agents to facilitate collaborative cancer immunotherapy. ACS Nano. 2025;19(18):17653\u201373. https:\/\/doi.org\/10.1021\/acsnano.5c01366.","journal-title":"ACS Nano"},{"issue":"10","key":"957_CR520","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/jfb16100381","volume":"16","author":"Y Yan","year":"2025","unstructured":"Yan Y, Chen Y, Huang L, Cai M, Yin X, Zhu YZ, et al. Bioengineered in situ-forming hydrogels as Smart drug delivery systems for postoperative breast cancer immunotherapy: from material innovation to clinical translation. JFB. 2025;16(10):381. https:\/\/doi.org\/10.3390\/jfb16100381.","journal-title":"JFB"},{"key":"957_CR521","doi-asserted-by":"publisher","first-page":"114159","DOI":"10.1016\/j.ejca.2024.114159","volume":"207","author":"N Verschoor","year":"2024","unstructured":"Verschoor N, Bos MK, Oomen-de Hoop E, Martens JW, Sleijfer S, Jager A, et al. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design. Eur J Cancer. 2024;207:114159.","journal-title":"Eur J Cancer"},{"issue":"20\u201322","key":"957_CR522","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/1750743X.2024.2430941","volume":"16","author":"N Burley","year":"2024","unstructured":"Burley N, Lee Y, Liu L, Gangi A, Nasseri Y, Atkins K, et al. ctDNA-guided adjuvant immunotherapy in colorectal cancer. Immunotherapy. 2024;16(20\u201322):1197\u2013202. https:\/\/doi.org\/10.1080\/1750743X.2024.2430941.","journal-title":"Immunotherapy"},{"issue":"12","key":"957_CR523","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1039\/D4BM00149D","volume":"12","author":"L Xu","year":"2024","unstructured":"Xu L, Zhou Y, Li N, Yang A, Qi H. Platelet membrane encapsulated curcumin nanomaterial-mediated specific thrombolysis and anti-thrombotic treatment among pregnant women. Biomater Sci. 2024;12(12):3163\u201374. https:\/\/doi.org\/10.1039\/D4BM00149D.","journal-title":"Biomater Sci"},{"issue":"1","key":"957_CR524","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers18010094","volume":"18","author":"C Theocharopoulos","year":"2025","unstructured":"Theocharopoulos C, Machairas N, Ziogas IA, Mungo B, Del Chiaro M, Glantzounis GK, et al. Personalizing treatment for pancreatic ductal adenocarcinoma: the emerging role of minimal residual disease in perioperative decision-making. Cancers. 2025;18(1):94. https:\/\/doi.org\/10.3390\/cancers18010094.","journal-title":"Cancers"},{"issue":"6","key":"957_CR525","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s12276-025-01465-6","volume":"57","author":"K Lv","year":"2025","unstructured":"Lv K, Zhang Y, Yin G, Li X, Zhong M, Zhu X, et al. Extracellular vesicles derived from lung M2 macrophages enhance group 2 innate lymphoid cells function in allergic airway inflammation. Exp Mol Med. 2025;57(6):1202\u201315. https:\/\/doi.org\/10.1038\/s12276-025-01465-6.","journal-title":"Exp Mol Med"},{"key":"957_CR526","doi-asserted-by":"publisher","unstructured":"Chen Y, Chen Q, Ma Y, Zhang C, Xu J, Li K, et al. In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy. Nat Commun. 2026;17(1). https:\/\/doi.org\/10.1038\/s41467-026-68490-5.","DOI":"10.1038\/s41467-026-68490-5"},{"key":"957_CR527","doi-asserted-by":"crossref","unstructured":"Conte M, Xella A, Woodall RT, Cassady KA, Branciamore S, Brown CE, et al. CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma. Math Biosci. 2025:109531.","DOI":"10.1016\/j.mbs.2025.109531"},{"key":"957_CR528","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163. https:\/\/doi.org\/10.3389\/fimmu.2024.1455163.","journal-title":"Front Immunol"},{"key":"957_CR529","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.2147\/IJN.S479438","volume":"19","author":"R Gao","year":"2024","unstructured":"Gao R, Lin P, Yang W, Fang Z, Gao C, Cheng B, et al. Bio-inspired Nanodelivery platform: platelet membrane-cloaked genistein nanosystem for targeted lung cancer therapy. IJN. 2024;19:10455\u201378. https:\/\/doi.org\/10.2147\/IJN.S479438.","journal-title":"IJN"},{"key":"957_CR530","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.2147\/IJN.S517753","volume":"Volume 20","author":"B Song","year":"2025","unstructured":"Song B, Na Y-G, Kim BJ, Jin M, Song YH, Kim D-E, et al. Platelet membrane-coated poly (lactic-co-glycolic acid) nanoparticles as a targeting drug delivery System for multidrug-resistant breast cancer. IJN. 2025;Volume 20:8529\u201345. https:\/\/doi.org\/10.2147\/IJN.S517753.","journal-title":"IJN"},{"key":"957_CR531","doi-asserted-by":"publisher","first-page":"1576042","DOI":"10.3389\/fimmu.2025.1576042","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Fang Q, Yuan J, Dai L, Luo R, Huang T, et al. Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study. Front Immunol. 2025;16:1576042. https:\/\/doi.org\/10.3389\/fimmu.2025.1576042.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR532","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-med-100223-090016","volume":"76","author":"N Hitchen","year":"2025","unstructured":"Hitchen N, Shahnam A, Tie J. Circulating tumor DNA: a Pan-cancer biomarker in solid tumors with prognostic and predictive value. Annu Rev Med. 2025;76(1):207\u201323. https:\/\/doi.org\/10.1146\/annurev-med-100223-090016.","journal-title":"Annu. Rev. Med"},{"issue":"7","key":"957_CR533","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","volume":"36","author":"C Valenza","year":"2025","unstructured":"Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, et al. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Ann Oncol. 2025;36(7):726\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.019.","journal-title":"Ann Oncol"},{"issue":"6","key":"957_CR534","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3390\/ijms26062486","volume":"26","author":"S Negro","year":"2025","unstructured":"Negro S, Pulvirenti A, Trento C, Indraccolo S, Ferrari S, Scarpa M, et al. Circulating tumor DNA as a real-time biomarker for minimal residual disease and recurrence prediction in stage II colorectal cancer: a systematic review and meta-analysis. IJMS. 2025;26(6):2486. https:\/\/doi.org\/10.3390\/ijms26062486.","journal-title":"IJMS"},{"issue":"14","key":"957_CR535","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.3390\/ijms25147743","volume":"25","author":"W Olejarz","year":"2024","unstructured":"Olejarz W, Sadowski K, Szulczyk D, Basak G. Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies. IJMS. 2024;25(14):7743. https:\/\/doi.org\/10.3390\/ijms25147743.","journal-title":"IJMS"},{"key":"957_CR536","doi-asserted-by":"publisher","first-page":"102908","DOI":"10.1016\/j.ctrv.2025.102908","volume":"135","author":"E Galli","year":"2025","unstructured":"Galli E, Patelli G, Villa F, Gri N, Mazzarelli C, Mangoni I, et al. Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: a systematic review. Cancer Treat Rev. 2025;135:102908. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102908.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"957_CR537","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41588-025-02351-7","volume":"57","author":"TN Aung","year":"2025","unstructured":"Aung TN, Monkman J, Warrell J, Vathiotis I, Bates KM, Gavrielatou N, et al. Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer. Nat Genet. 2025;57(10):2482\u201393. https:\/\/doi.org\/10.1038\/s41588-025-02351-7.","journal-title":"Nat Genet"},{"issue":"4","key":"957_CR538","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10585-023-10246-2","volume":"41","author":"W Liu","year":"2024","unstructured":"Liu W, Puri A, Fu D, Chen L, Wang C, Kellis M, et al. Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Clin Exp Metastasis. 2024;41(4):313\u201332. https:\/\/doi.org\/10.1007\/s10585-023-10246-2.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"957_CR539","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024;35(6):508\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.007.","journal-title":"Ann Oncol"},{"key":"957_CR540","doi-asserted-by":"publisher","first-page":"1554871","DOI":"10.3389\/fimmu.2025.1554871","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Song Z, Zhang Y, Zhang C, Xue Q, Zhang G, et al. Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer. Front Immunol. 2025;16:1554871. https:\/\/doi.org\/10.3389\/fimmu.2025.1554871.","journal-title":"Front Immunol"},{"issue":"1","key":"957_CR541","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, Liu L, Zhang J, Sun L, Shu W, Yang Z, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J Hematol Oncol. 2025;18(1):84. https:\/\/doi.org\/10.1186\/s13045-025-01732-z.","journal-title":"J Hematol Oncol"},{"key":"957_CR542","doi-asserted-by":"publisher","unstructured":"Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):e010311. https:\/\/doi.org\/10.1136\/jitc-2024-010311.","DOI":"10.1136\/jitc-2024-010311"},{"key":"957_CR543","doi-asserted-by":"publisher","first-page":"114225","DOI":"10.1016\/j.ejca.2024.114225","volume":"209","author":"M Lawler","year":"2024","unstructured":"Lawler M, Keeling P, Kholmanskikh O, Minnaard W, Moehlig-Zuttermeister H, Normanno N, et al. Empowering effective biomarker-driven precision oncology: a call to action. Eur J Cancer. 2024;209:114225. https:\/\/doi.org\/10.1016\/j.ejca.2024.114225.","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"957_CR544","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2019.37.15_suppl.2542","volume":"37","author":"MAJ Iafolla","year":"2019","unstructured":"Iafolla MAJ, Yang C, Dashner S, Xu W, Hansen AR, Bedard PL, et al. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P). JCO. 2019;37(15_suppl):2542\u20132542. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2542.","journal-title":"JCO"},{"key":"957_CR545","doi-asserted-by":"publisher","unstructured":"Esposito Abate R, Pasquale R, Sacco A, Simeon V, Maiello MR, Frezzetti D, et al. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN path initiative. J Immunother Cancer. 2024;12(2):e007800. https:\/\/doi.org\/10.1136\/jitc-2023-007800.","DOI":"10.1136\/jitc-2023-007800"},{"issue":"8","key":"957_CR546","doi-asserted-by":"publisher","first-page":"447","DOI":"10.34172\/aim.2023.68","volume":"26","author":"H Razzaghi","year":"2023","unstructured":"Razzaghi H, Khabbazpour M, Heidary Z, Heiat M, Shirzad Moghaddam Z, Derogar P, et al. Emerging role of tumor-educated platelets as a New liquid Biopsy tool for colorectal cancer. Arch Iran Med. 2023;26(8):447\u201354. https:\/\/doi.org\/10.34172\/aim.2023.68.","journal-title":"Arch Iran Med"},{"issue":"8","key":"957_CR547","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/j.apsb.2022.01.005","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhu Y, Wei X, Chen X, Li Y, Zhu Y, et al. Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model. Acta Pharmaceutica Sin. B. 2022;12(8):3427\u201347. https:\/\/doi.org\/10.1016\/j.apsb.2022.01.005.","journal-title":"Acta Pharmaceutica Sin. B"},{"issue":"1","key":"957_CR548","doi-asserted-by":"publisher","first-page":"9359","DOI":"10.1038\/s41598-023-35818-w","volume":"13","author":"M Antunes-Ferreira","year":"2023","unstructured":"Antunes-Ferreira M, D\u2019Ambrosi S, Arkani M, Post E, In \u2018t Veld S, Ramaker J, et al. Tumor-educated platelet blood tests for non-small cell lung cancer detection and management. Sci Rep. 2023;13(1):9359. https:\/\/doi.org\/10.1038\/s41598-023-35818-w.","journal-title":"Sci Rep"},{"key":"957_CR549","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.1016\/j.jlb.2025.100326","volume":"10","author":"K Morris","year":"2025","unstructured":"Morris K, Li C, Sarangi S, Papa AL. Phenotype independent capture of circulating tumor cell using magnetic platelet decoys. J Sport Hist Liquid Biopsy. 2025;10:100326. https:\/\/doi.org\/10.1016\/j.jlb.2025.100326.","journal-title":"J Sport Hist Liquid Biopsy"},{"key":"957_CR550","doi-asserted-by":"publisher","unstructured":"Wang Y, Wu H, Zhou Z, Maitz MF, Liu K, Zhang B, et al. A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants. Sci Adv. 2022;8(9):eabm3378. https:\/\/doi.org\/10.1126\/sciadv.abm3378.","DOI":"10.1126\/sciadv.abm3378"},{"key":"957_CR551","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.04.044","volume":"135","author":"MF Maitz","year":"2017","unstructured":"Maitz MF, Zitzmann J, Hanke J, Renneberg C, Tsurkan MV, Sperling C, et al. Adaptive release of heparin from anticoagulant hydrogels triggered by different blood coagulation factors. Biomaterials. 2017;135:53\u201361. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.04.044.","journal-title":"Biomaterials"},{"issue":"6","key":"957_CR552","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/jnis-2024-021836","volume":"17","author":"MF Maitz","year":"2025","unstructured":"Maitz MF, Kaiser DPO, Cuberi A, Weich Hern\u00e1ndez R, M\u00fchl-Benninghaus R, Tomori T, et al. Enhancing thromboresistance of neurovascular nickel-titanium devices with responsive heparin hydrogel coatings. J NeuroIntervent Surg. 2025;17(6):625\u201331. https:\/\/doi.org\/10.1136\/jnis-2024-021836.","journal-title":"J NeuroIntervent Surg"},{"key":"957_CR553","doi-asserted-by":"publisher","first-page":"125733","DOI":"10.1016\/j.ijpharm.2025.125733","volume":"679","author":"S Mantry","year":"2025","unstructured":"Mantry S, Das PK, Sankaraiah J, Panda S, Silakabattini K, Reddy Devireddy AK, et al. Advancements on heparin-based hydrogel\/scaffolds in biomedical and tissue engineering applications: delivery carrier and pre-clinical implications. Int J Multiling Pharm. 2025;679:125733. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125733.","journal-title":"Int J Multiling Pharm"},{"key":"957_CR554","doi-asserted-by":"publisher","first-page":"101076","DOI":"10.1016\/j.iotech.2025.101076","volume":"28","author":"J Chiffelle","year":"2025","unstructured":"Chiffelle J, Genolet R, Michielin O, Harari A. Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy. Immuno-Oncol Technol. 2025;28:101076. https:\/\/doi.org\/10.1016\/j.iotech.2025.101076.","journal-title":"Immuno-Oncol Technol"},{"issue":"1","key":"957_CR555","doi-asserted-by":"publisher","first-page":"233","DOI":"10.62347\/ZSOO2247","volume":"15","author":"M Zhu","year":"2025","unstructured":"Zhu M, Hu Y, Gu Y, Lin X, Jiang X, Gong C, et al. Role of amino acid metabolism in tumor immune microenvironment of colorectal cancer. Am J Cancer Res. 2025;15(1):233\u201347.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"957_CR556","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1078-0432.CCR-22-2469","volume":"29","author":"ML Frank","year":"2023","unstructured":"Frank ML, Lu K, Erdogan C, Han Y, Hu J, Wang T, et al. T-Cell receptor repertoire sequencing in the era of cancer immunotherapy. Clin Cancer Res. 2023;29(6):994\u20131008. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2469.","journal-title":"Clin Cancer Res"},{"key":"957_CR557","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/LCTT.S539777","volume":"16","author":"E Elayeh","year":"2025","unstructured":"Elayeh E, Aleidi SM, Aboud O, Semreen MH, Bustanji YK, Dahabiyeh LA. Integrated multi-omics approaches for predicting immune checkpoint inhibitor response in NSCLC \u2013 insights from genomics, proteomics, and metabolomics. LCTT. 2025;16:167\u201398. https:\/\/doi.org\/10.2147\/LCTT.S539777.","journal-title":"LCTT"},{"issue":"2","key":"957_CR558","doi-asserted-by":"publisher","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","volume":"33","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH. Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Ther Oncol. 2025;33(2):200980. https:\/\/doi.org\/10.1016\/j.omton.2025.200980.","journal-title":"Mol Ther Oncol"},{"key":"957_CR559","doi-asserted-by":"publisher","first-page":"1612248","DOI":"10.3389\/fbioe.2025.1612248","volume":"13","author":"AL Weltin","year":"2026","unstructured":"Weltin AL, De Graaf Y, Goudarzi A, M\u00fcller M, Herbst L, Nie\u00dfing B, et al. Industrializing CAR-T cell therapy: impact of automation on cost and space efficiency of manufacturing facilities. Front Bioeng Biotechnol. 2026;13:1612248. https:\/\/doi.org\/10.3389\/fbioe.2025.1612248.","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00957-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:05:11Z","timestamp":1787695511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":559,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00957-5","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}